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Abstract 
Cytoplasmic inclusions and fibrils of the microtubule-associated protein tau (tau protein) are a key 
neuropathological hallmark in tauopathies, including Alzheimer’s disease, chronic traumatic 
encephalopathy, and amyotrophic lateral sclerosis with cognitive impairment. Previous research 
has demonstrated that the phosphorylation of tau protein at Thr175 is sufficient for the initiation of 
fibril formation both in vitro and in vivo. Here we use mutated tau protein constructs to demonstrate 
that phosphorylation at Thr175 results in the aberrant exposure of an N-terminal phosphatase-
activating domain (PAD). The tau PAD interacts with protein phosphatase 1 (PP1) leading to the 
activation of glycogen synthase kinase 3β (GSK3β), and subsequent fibril formation. Experimental 
rodent traumatic brain injury initiated the development of pThr175 tau fibrils in vivo, and associates 
with PAD exposure in the acute phases following injury. These data collectively suggest that 
pThr175 tau formation might initiate a pathological PAD-mediated neurotoxicity, resulting in the 
formation of tau fibrils.  
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Laypersons Summary 
Traumatic brain injury (TBI) causes more disability amongst Canadians than any other 
neurological condition. In some instances, TBI can cause a molecule in the brain called tau to 
clump together. These clumps are called aggregates, and they can kill brain cells over time. Tau 
aggregates are found in numerous neurodegenerative conditions, including Alzheimer’s disease, 
chronic traumatic encephalopathy (CTE), and in amyotrophic lateral sclerosis (ALS/’Lou Gehrig’s 
disease’) with cognitive impairment (ALSci). Although it is well-established that tau aggregates 
are a feature of these conditions, the mechanisms by which TBI causes individual tau molecules 
to clump together are not well-understood. Our previous studies have shown that in these diseases, 
a specific part of tau has a phosphate group added onto it- specifically the threonine residue at 
position 175 on tau (termed ‘pThr175 tau’). This phosphate addition is only present in individuals 
with diseases, and we have shown previously that this specific modification contributes to tau 
aggregate formation. The goal of the current master’s thesis is to better understand how pThr175 
tau leads to the formation of tau aggregates.  
In the current thesis, I demonstrate that pThr175 tau has a different shape than tau without 
the phosphate group added. This change in shape causes tau to bind to and activate a series of other 
molecules in the cell which then add many phosphate molecules to tau, causing aggregation. I then 
show that the formation of tau aggregates could be reduced by making specific modifications to 
tau that prevent interactions with these other molecules. I then demonstrate that giving a TBI to a 
rat causes tau aggregates to form. Moreover, pThr175 tau forms early after a TBI, and is associated 
with a change in tau’s shape, just as in our previous experiments.  
These studies collectively suggest that adding a phosphate group to Thr175 on tau changes 
the shape of tau and aberrantly activates other molecules. These other molecules then further 
modify tau and cause aggregates to form. Understanding this mechanism better allows us to 
identify specific changes to tau in the brain following TBI that may be stopped to prevent long-
term disability in humans.  
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Epigraph 
 
“After you have exhausted what there is in business, politics, conviviality, and so on - have found 
that none of these finally satisfy, or permanently wear - what remains? Nature remains.” 
- Walt Whitman 
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INTRODUCTION AND BACKGROUND 
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The Microtubule-Associated Protein Tau (MAPT) 
1.1.1 Tau gene and isoforms 
The human microtubule-associated protein tau (tau protein) is encoded by the MAPT gene located 
on chromosome 17 at band position 17q21 (Neve, Harris, Kosik, Kurnit, & Donlon, 1986). 
Alternative splicing of the 16 exons present in tau mRNA produces multiple unique isoforms 
(Andreadis, Brown, & Kosik, 1992; Himmler, Drechsel, Kirschner, & Martin, 1989). Exons 2 and 
3 encode two domains located near the N-terminus (termed N-terminal repeats), which can be 
alternatively spliced to produce proteins with three possible numbers of N-terminal repeats: 0N 
(neither exon 2 nor 3 present), 1N (exon 2 present), or 2N (exons 2 and 3 present) (Andreadis, 
Broderick, & Kosik, 1995). Exons 9-12 encode four imperfectly-repeating microtubule binding 
domains (‘R groups’). Exon 10 encodes the second of four microtubule-binding domains and can 
be spliced to produce either 3R (exon 10 absent) or 4R (exon 10 present) tau protein based on the 
number of microtubule-binding domains incorporated during translation (Himmler et al., 1989). 
Thus, in total there are six tau protein isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R; Figure 
1.1) (Goedert, Spillantini, Jakes, Rutherford, & Crowther, 1989; Goedert, Spillantini, Potier, 
Ulrich, & Crowther, 1989; Kosik, Orecchio, Bakalis, & Neve, 1989). In healthy adult humans, the 
3R:4R expression ratio is approximately 1:1 (Goedert, Spillantini, Jakes, et al., 1989; Kosik, 
Orecchio, et al., 1989). Intriguingly, tau isoform expression changes throughout development, with 
fetal tau being comprised of 0N3R tau protein with increasing levels of 4R tau being expressed in 
adulthood (Goedert, Spillantini, Jakes, et al., 1989; Kosik, Orecchio, et al., 1989).  
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Figure 1.1 Schematic representation of the mRNA transcript and translated proteins for human 
tau. The mRNA transcript represented produces full-length 2N4R human tau protein. Exons 2 and 
3 correspond with the N1 and N2 N-terminal repeat regions, and exon 10 corresponds with the R2 
microtubule-binding domain. Alternative splicing results in six tau protein isoforms, with each 
translated protein schematically represented for each isoform. The sizes of exons in this diagram 
are not in scale with true transcript lengths.  
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1.1.2 Tau protein structure 
Tau protein is subdivided into a series of domains based on primary structure  
(Figure 1.2). Considering the longest tau protein isoform (2N4R, 441 amino acids), the N-terminus 
possesses an acidic region containing the phosphatase-activating domain (PAD) that consists of 
amino acids (aa) 2-18 (Kanaan et al., 2011). The two N-terminal repeats span aa 45-103 with a 
small linker region separating them (Goedert, Spillantini, Jakes, et al., 1989; Goedert, Spillantini, 
Potier, et al., 1989; Himmler et al., 1989; Kosik, Kowall, & McKee, 1989). The N-terminal repeats 
are followed by a proline-rich region comprised of aa 103-244. This region contains many Ser and 
Thr residues that proline-directed kinases are known to phosphorylate (Goode et al., 1997). The 
microtubule-binding region spans aa 244-370 and contains four imperfectly-repeated domains that 
are critical for microtubule binding and stabilization within neurons (Lee, Neve, & Kosik, 1989). 
Finally, the microtubule-binding domains are followed by a C-terminal segment spanning aa 368-
441. 
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Figure 1.2 Schematic representation of the primary structure of the longest tau protein isoform 
(2N4R) with domains indicated. The diagram is scaled to represent size based on amino acid 
number. PAD = phosphatase-activating domain, N1 and N2 = N-terminal repeats, R1-R4 = 
microtubule-binding domains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Tau is a largely hydrophilic protein with 76.8% of its amino acids possessing polarity. As 
a result, experiments aimed at assessing the secondary and tertiary structures of monomeric tau 
protein in aqueous solution have yielded largely indeterminate results. Initial circular 
dichromatism studies on monomeric tau did not reveal any significant secondary or tertiary 
structures (Cleveland, Hwo, & Kirschner, 1977a). Subsequent investigations have utilized various 
other methods to examine the tertiary structure of tau, including Fourier transform infrared 
spectroscopy (Ramachandran, 2017), proton nuclear magnetic resonance (NMR) spectroscopy 
(Landrieu et al., 2010), and X-ray diffraction (Cehlar, Skrabana, Kovac, Kovacech, & Novak, 
2012). These experiments have supported the conclusion that tau is an intrinsically disordered 
protein (“IDP”, reviewed in Skrabana, Sevcik, & Novak, 2006), and does not possess any rigid 
secondary or tertiary structure. However, more recent investigations utilizing fluorescence 
resonance energy transfer (FRET) in solution to examine the proximity of specific amino acid 
residues have demonstrated that tau protein possesses a native hairpin conformation, in which the 
Thr17/Tyr18 residues within the N-terminal acidic region interact with Val432 on the C-terminal end 
(Jeganathan, von Bergen, Brutlach, Steinhoff, & Mandelkow, 2006). Although this conformation 
is not rigid, the observations from this investigation support the view that tau protein is not a 
random coil, and possesses some – although, likely dynamic – tertiary structure (Figure 1.3).   
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Figure 1.3 Schematic representation of tau protein in linearized and native hairpin conformation. 
Representations are presented from N- to C-terminus. PAD = phosphatase-activating domain. 
MTBR = microtubule-binding repeats.  
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1.1.3 Tau protein function under physiological conditions 
Tau protein has traditionally been described as a microtubule-associated protein (MAP) for its 
ability to bind to and stabilize microtubules. Indeed, early experimental investigations 
demonstrated that the presence of tau protein decreased the concentration at which microtubules 
polymerized in vitro, prompting further investigation of the role of tau protein in microtubule 
formation and maintenance (Cleveland et al., 1977a; Cleveland, Hwo, & Kirschner, 1977b; 
Fellous, Francon, Lennon, & Nunez, 1977; Weingarten, Lockwood, Hwo, & Kirschner, 1975). In 
neurons, microtubule and cytoskeletal dynamics play an important role in axonal morphogenesis 
in the developing brain (Sakakibara & Horwitz, 2006). Tau protein is particularly abundant in 
neuronal axonal projections and is important for microtubule stabilization and organization within 
these structures (Binder, Frankfurter, & Rebhun, 1985). Tau protein binds to microtubules via the 
three or four microtubule-binding domains present, depending on tau protein isoform (3R, or 4R) 
(Lee et al., 1989). Binding to microtubules is stronger for 4R tau protein isoforms when compared 
to 3R (Goedert & Jakes, 1990; Goode & Feinstein, 1994; Schoch et al., 2016).  
In addition to its importance for microtubule polymerization and stabilization within 
neurons, the role of tau protein as an important signalling molecule has also been explored (Alonso 
et al., 2010; Jesús Avila, Simón, Díaz-Hernández, Pintor, & Hernández, 2014; Khan & Bloom, 
2016). One such study utilized a tau protein knock-out murine model and found that deletion 
contributed to diminished insulin response of mouse hippocampal neurons, resulting in a reduction 
of insulin-induced long-term depression (LTD) ex vivo (Marciniak et al., 2017). Recently, the 
potential for tau protein to modulate changes in vesicular fast axonal transport (FAT) has been 
extensively investigated (Cuchillo-Ibanez et al., 2008; Kanaan et al., 2011, 2012; LaPointe et al., 
2009), although this regulation has not been demonstrated under physiological conditions. These 
experiments have illustrated that tau protein is directly involved in critical signalling pathways 
within neurons and may not be exclusively involved in microtubule polymerization and 
stabilization. 
1.1.4 Tau protein regulation by phosphorylation 
The function and tertiary structure of tau proteins in physiological conditions are largely dependant 
upon post-translational modifications. These modifications change steric or electrostatic 
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interactions with other proteins in the cell and other tau monomers. Phosphorylation is the most 
extensively investigated post-translational modification to tau protein. It is well-established that 
the net effect of phosphorylation of tau is a decrease in affinity for microtubules, thereby reducing 
microtubule polymerization (Biernat, Gustke, Drewes, Mandelkow, & Mandelkow, 1993; 
Bramblett et al., 1993; Cleveland et al., 1977a, 1977b; Drubin & Kirschner, 1986). Tau protein 
contains 85 Thr, Ser, or Tyr residues that can be phosphorylated to regulate tau protein function. 
Physiologically, tau protein phosphorylation is maintained at an approximate molar ratio of 2-3:1 
phosphates:tau protein. However, in the disease state, tau protein phosphorylation can be increased 
to a ratio of approximately 5-9:1 (Köpke et al., 1993), and is termed “hyperphosphorylated” tau.  
Hyperphosphorylated tau proteins within neuronal inclusions are a neuropathological 
feature of a number of neurodegenerative conditions, termed ‘tauopathies’ (Alonso et al., 2010; 
Hanger, Betts, Loviny, Blackstock, & Anderton, 1998; Kimura, Ishiguro, & Hisanaga, 2014; 
Landrieu et al., 2011; Ponce-Lopez, Hong, Abascal-Díaz, & Meneses, 2017; Zhao et al., 2017). 
Importantly, results from both in vivo (Nie, Wang, Liu, Perrett, & He, 2007) and in vitro (Wang, 
Biernat, Pickhardt, Mandelkow, & Mandelkow, 2007) experimental models of tau-mediated 
neurodegeneration have suggested that the abnormal processing of tau protein results in 
cytotoxicity and neuronal death. This has resulted in the hypothesis that tau protein dysregulation 
may be central to the initiation or progression of neurodegeneration in tauopathy (reviewed in Guo, 
Noble, & Hanger, 2017) and highlights the need to better understand the roles of tau protein in the 
diseased brain. 
1.1.5 Tau protein kinases and phosphatases 
Numerous kinases that phosphorylate tau protein, largely from the mitogen-activated protein 
kinase (MAPK) family, have been identified as being upregulated in tauopathies (Avila, 2008; 
Dolan & Johnson, 2010; Ferrer et al., 2004; Lucke-Wold et al., 2014; Martin et al., 2013). Among 
the most extensively investigated are glycogen synthase kinase 3β (GSK3β; section 1.2) (Beurel, 
Grieco, & Jope, 2015; Cho & Johnson, 2003, 2004; Hermida, Dinesh Kumar, & Leslie, 2017; 
Hooper, Killick, & Lovestone, 2008; Moszczynski et al., 2014; Noh et al., 2013; Ponce-Lopez et 
al., 2017),  c-Jun N-terminal kinase (JNK) (Ferrer, 2004; Rahman, Zhang, Mody, Su, & Das, 2012; 
Tran, Sanchez, & Brody, 2012), and extracellular signal-regulated kinase (ERK 1/2) (Guise, 
Braguer, Carles, Delacourte, & Briand, 2001; Hanger et al., 1998; Kins, Kurosinski, Nitsch, & 
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Götz, 2003; Qi et al., 2016). Given the large number of phosphorylation sites on tau protein, 
understanding the relationship between the activity of tau protein kinases and pathologic 
phosphorylation events is paramount in the identification of pharmacologic targets that may 
prevent or slow tau-mediated neurodegeneration.  
Given the profound impact of tau protein phosphorylation on neuronal microtubule 
homeostasis, many researchers have also investigated the role of phosphatase dysregulation in 
tauopathies.  For example, protein phosphatase 2A (PP2A) is downregulated in some patients with 
Alzheimer’s disease (Landrieu et al., 2011; Martin, Latypova, Wilson, Magnaudeix, Perrin, & 
Terro, 2013; Ponce-Lopez et al., 2017). Additionally, in vitro knockdown experiments have 
demonstrated that a reduction of PP2A activity is sufficient for the induction of tau aggregate 
formation (Seo et al., 2017). Protein phosphatase 1 (PP1) is known to associate with the N-
terminus of tau protein (Combs, Hamel, & Kanaan, 2016; Kanaan et al., 2011, 2012), and is 
directed toward microtubules (Liao, Li, Brautigan, & Gundersen, 1998). Therefore, tau protein is 
under constant regulation by both kinase and phosphatase activity which, if dysregulated, can 
contribute to tau hyperphosphorylation and the development of tau protein pathology (Liu, Iqbal, 
Grundke-Iqbal, Rossie, & Gong, 2005). 
1.1.6 Pathologic tau and tauopathy 
Proteinopathies are a cluster of neurodegenerative conditions characterized by the aggregation and 
accumulation of highly stable misfolded proteins within neurons and glial cells (Ross & Poirier, 
2004). Neurofibrillary tangles were initially described as a hallmark pathology in Alzheimer’s 
disease and consist of hyperphosphorylated tau proteins (Bancher et al., 1989; Jellinger, 1998; Lee, 
Goedert, & Trojanowski, 2001) that commonly form aggregated sarkosyl-insoluble polymers 
(Greenberg & Davies, 1990). Neurofibrillary tangles and tau immunoreactive astrocytes are key 
neuropathological observations in chronic traumatic encephalopathy (CTE), a traumatic brain 
injury (TBI)-induced neurodegenerative condition (McKee, Stein, Kiernan, & Alvarez, 2015; 
Moszczynski et al., 2018; Omalu et al., 2005). Understanding the biochemical consequences of 
specific tau protein phosphorylation events is essential in our understanding of neurofibrillary 
tangle formation. 
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Specific Ser, Thr, and Tyr residues (labeled by their position on the longest tau protein 
isoform, 2N4R) are more frequently phosphorylated in the disease state than in healthy individuals. 
Some examples include the AT8 (‘Alzheimer’s tau 8’) epitope that recognizes pSer199/pSer202 and 
pThr205 and the AT180 epitope (pThr231 tau) that is robustly associated with fibril formation 
(Alonso et al., 2010; Cho & Johnson, 2004; Gohar et al., 2009; Moszczynski, McKee, Strong, & 
Strong, 2016). Importantly, pThr231 tau is elevated in neurons with neurofibrillary tangles and in 
foetal tau – which is commonly hyperphosphorylated (Kenessey & Yen, 1993) – but is also present 
under physiological conditions (Hanger et al., 1998; Reynolds, Betts, Blackstock, Nebreda, & 
Anderton, 2000). This indicates that phosphorylation of tau at this residue is not exclusively 
pathological. Intriguingly, in Alzheimer’s disease, analysis of the hyperphosphorylated tau 
proteins present in neurofibrillary tangles demonstrate immunoreactivity for a triplet motif of 
mainly three tau protein isoforms, termed “paired-helical filaments” (PHF-tau) (Kolarova, García-
Sierra, Bartos, Ricny, & Ripova, 2012; Selkoe, 1986). This is in contrast to the sarkosyl-insoluble 
hyperphosphorylated tau protein fractions derived from the brains of individuals with CTE or 
amyotrophic lateral sclerosis (ALS) with cognitive impairment (ALSci), which include all six tau 
isoforms (Moszczynski et al., 2018; Strong et al., 2006). Our lab has previously identified a 
pathological tau protein phosphoepitope – pThr175 tau – that is present in numerous tauopathies, 
but absent in healthy controls (Moszczynski et al., 2018a; Moszczynski et al., 2017) and foetal tau 
(Reynolds et al., 2000).  
1.1.7 Other tau protein post-translational modifications 
Other post-translational modifications to tau include acetylation (Cohen et al., 2011), and O-
glycosylation (Arnold et al., 1996), each having different functional outcomes in physiological and 
pathological conditions. For example, the acetylation of tau protein is differentially regulated in 
disease states, such as in Alzheimer’s disease and CTE (Lucke-Wold et al., 2017), and has the 
effect of dysregulating tau protein function and degradation (Cohen et al., 2011; Cook et al., 2014; 
Gorsky, Burnouf, Dols, Mandelkow, & Partridge, 2016). Specifically, one study demonstrated that 
the acetylation of tau protein at numerous residues was elevated in Alzheimer’s disease brains, and 
the inhibition of SIRT1 deacetylase enzyme in vitro increased acetylation resulting in a reduction 
of tau protein clearance by the proteasome (Min et al., 2010). These results suggest that acetylation 
events can lead to the accumulation of tau protein in Alzheimer’s disease, thereby contributing to 
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the development of tau protein pathology. Experiments aimed at elucidating the effect of O-
glycosylation on tau protein function have suggested that this post-translational modification may 
result in an increase in tau-tubulin interactions  (Arnold et al., 1996; Jesús Avila, Lucas, Pérez, & 
Hernández, 2004; Takahashi et al., 1999; Wang, Grundke-Iqbal, & Iqbal, 1996). Additionally, the 
truncation of tau protein has been examined extensively for its relevance to the disease state and 
the formation of neurofibrillary tangles (Flores-Rodríguez et al., 2015). Intriguingly, whereas tau 
protein phosphorylation, acetylation, and O-glycosylation all contribute to the regulation of tau 
protein in physiological conditions, the truncation of tau protein appears to be uniquely 
pathological (García-Sierra, Mondragón-Rodríguez, & Basurto-Islas, 2008; Kovacech & Novak, 
2010). Better understanding the roles of post-translational modifications to tau protein in both 
physiological and pathological conditions is vital to understanding the mechanisms by which 
tauopathy develops in humans. 
1.1.8 Tau protein regulation of fast axonal transport (FAT) 
Tau protein phosphorylation and structural changes also play a role in regulating the transport of 
vesicles along axonal processes and the unloading of cargo from kinesin motor proteins. Fast 
axonal transport (FAT) is the active process by which membrane-bound organelles are moved 
along microtubules by motor proteins called kinesin or dynein, which move vesicles either away 
from or toward the cell body, respectively (Stenoien & Brady, 1999). Anterograde FAT can move 
vesicles containing synthesized components vital to synaptic function at a rate of 2-5µm per second 
(Brady, 1991), providing a critical method of regulating axonal and synaptic function and integrity. 
Recent studies have examined the role of aberrant exposure of the tau protein N-terminal 
PAD in tau-mediated neurotoxicity. These investigations have demonstrated that the unfolding of 
tau protein’s hairpin conformation and the aberrant exposure of the PAD results in inhibition of 
anterograde, but not retrograde FAT in giant squid axons (Combs et al., 2016; Kanaan et al., 2011). 
Exposure of the PAD is shown to be increased in the early stages of tau neurofibrillary tangle 
formation and contribute to the aberrant activation of GSK3β resulting in premature unloading of 
cargo from kinesin (Kanaan et al., 2011). Mechanistically, this was demonstrated to occur via 
interactions between the tau PAD and axonal PP1, resulting in phosphatase activation. 
Subsequently, activated PP1 removes an inhibitory phosphate from the Ser9 residue of GSK3β 
(Kanaan et al., 2011), which results in an increase in GSK3β activity (Hernández, Langa, Cuadros, 
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Avila, & Villanueva, 2010). Once activated, GSK3β phosphorylates kinesin light chain, resulting 
in the premature release of vesicles and impaired anterograde FAT (Combs et al., 2016). 
Importantly, this PAD-mediated inhibition of FAT can be abolished by the phosphorylation of tau 
protein at Tyr18, potentially by interfering with the PAD-PP1 interaction (see Kanaan et al., 2012). 
Therefore, tau protein is not only involved in the structural stabilization of microtubules along 
axonal processes but may also be involved in the inhibition of transport along the axon in 
pathological conditions, contributing to neurotoxicity. 
1.1.9 Summary  
In summary, tau protein is a critical element of structural and functional homeostasis within 
neurons. Tauopathies are characterized by deposits of hyperphosphorylated tau protein and 
increases in the activity of tau kinases, such as GSK3β. However, the mechanisms by which the 
aberrant phosphorylation of tau protein contributes to aggregation, fibril formation, and 
cytotoxicity remain elusive. Investigations examining the contribution of specific tau protein 
phosphorylation events toward neurodegenerative processes are thus required to better understand, 
treat, and prevent the initiation and progression tauopathies in humans. 
1.2 Glycogen Synthase Kinase 3β (GSK3β) 
1.2.1 GSK3β relevance to tauopathies 
GSK3β is a ubiquitously expressed Ser-Thr kinase involved in numerous cell-signalling pathways 
critical to physiological function. Initially identified for its involvement in Wnt and insulin 
signaling (Embi, Rylatt, & Cohen, 1980; Wu & Pan, 2010), it is now recognized that the activity 
of GSK3β is elevated in many tauopathies, including Alzheimer’s disease (Hooper et al., 2008), 
CTE (Lucke-Wold et al., 2014; Moszczynski, Strong, et al., 2018; Shim & Stutzmann, 2016), and 
ALSci (Yang, Leystra-Lantz, & Strong, 2008). The co-occurrence of both hyperphosphorylated 
tau proteins and an aberrant increase in activity of GSK3β (a tau protein kinase) in tauopathies has 
prompted considerable investigation concerning the relationship between these two proteins in 
neurodegenerative processes (reviewed in Hooper et al., 2008).  
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1.2.2 The regulation of GSK3β 
GSK3β phosphorylates a very high number of proteins within the cell. In fact, a theoretical analysis 
identified nearly 500 predicted phosphorylation targets for GSK3β, about 10 times that of the 
average for other kinases within the cell (Linding et al., 2007). Most phosphorylation targets for 
GSK3β require a phosphorylated prime sequence consisting of a phosphorylated Thr or Ser four 
amino acids downstream of the target residue (T/S-X-X-X-pT/S) (Haar et al., 2001). The 
phosphorylated amino acid of the target protein interacts with an N-terminal primed 
phosphorylation binding site on GSK3β, and the protein is curved through the GSK3β active site 
to phosphorylate the target residue approximately four amino acids upstream (Figure 1.4A) (Dajani 
et al., 2003; Frame, Cohen, & Biondi, 2001). However, it is important to note that GSK3β can also 
phosphorylate unprimed substrates. Indeed, the presence of an acidic amino acid in place of a 
primed residue will also result in phosphorylation of the substrate by GSK3β (Cho & Johnson, 
2004). Therefore, although primed phosphorylation contributes to an increased propensity of 
GSK3β to phosphorylate its target, it is not required for phosphorylation.  
The activity of GSK3β is controlled by post-translational modification at two key 
phosphorylation sites. Firstly, the Tyr216 residue lies within the active site and contains the 
phosphate that is transferred to the substrate. Therefore, Tyr216 phosphorylation is required for 
GSK3β activity (Hughes, Nikolakaki, Plyte, Totty, & Woodgett, 1993). Intriguingly, during 
translation, GSK3β acts as a Tyr kinase and autophosphorylates its Tyr216 residue resulting in this 
kinase being active upon translation (Cole, Frame, & Cohen, 2004). The second regulatory 
mechanism involves phosphorylation at Ser9, which allows the N-terminal end of GSK3β to fit 
within the primed phosphorylation site (Figure 1.4B). The effect of Ser9 phosphorylation is a 
competitive inhibition of the phosphorylation of primed substrates by GSK3β (Frame et al., 2001). 
As such, regulation of GSK3β activity occurs primarily by phosphorylating or dephosphorylating 
the Ser9 residue. It is, however, important to note that phosphorylation at Ser9 does not abolish all 
primed GSK3β phosphorylation events, as increasing the concentration of substrate may 
outcompete the pSer9 residue for the primed phosphorylation site. 
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Figure 1.4 Phosphorylation of primed substrate by GSK3β. A) The primed substrate binding 
domain of GSK3β consists of a hydrophilic pocket capable of stabilizing the charge of a phosphate 
group on the substrate. This stabilization holds the target protein in place so the active site residue 
(Tyr216) can phosphorylate the substrate approximately four amino acids upstream of the primed 
site. B) When the primed phosphorylation binding site of GSK3β is pre-phosphorylated (pSer9), 
substrate binding is competitively inhibited. As a result, stabilization of the target protein cannot 
occur and primed phosphorylation is blocked.  
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1.2.3 GSK3β is an important tau kinase 
Tau protein is phosphorylated by GSK3β under a number of experimental and physiological 
conditions. One such experiment utilized a Drosophila model to show an enhancement of 
neurofibrillary tangle formation when over expressing tau protein and GSK3β together (Jackson 
et al., 2002), whereas the expression of tau alone did not initiate neurofibrillary tangle formation 
in a similar model (Wittmann et al., 2001). This effect has been replicated in a knock-in murine 
model, demonstrating that the co-expression of human tau protein with GSK3β increased the 
development tau pathology and neurodegeneration (Engel, Lucas, et al., 2006). In vitro 
experiments have since confirmed that tau protein is directly phosphorylated by GSK3β and that 
this phosphorylation contributes to the development of neurofibrillary pathology (Rankin, Sun, & 
Gamblin, 2007). This is supported by the finding that GSK3β phosphorylates many of the residues 
found in PHF tau, including Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 (Song & Yang, 1995). 
The apparent relationship between the phosphorylation of tau protein by GSK3β and the 
development of tau pathology suggests that inhibition of GSK3β may be beneficial in reducing or 
preventing the development of neurofibrillary tangles. Indeed, the inhibition of GSK3β by lithium 
reduced GSK3β-mediated tau neurofibrillary tangle development in many in vivo (Engel, Goñi-
Oliver, Lucas, Avila, & Hernández, 2006; Shim & Stutzmann, 2016) and in vitro (Moszczynski et 
al., 2014; Xiong et al., 2013) model systems. Building on these experimental observations, the 
possibility of using of lithium to treat individuals with suspected tauopathy – specifically, those 
with CTE – was explored in a review by Leeds and colleagues (2014). 
1.3 Chronic Traumatic Encephalopathy (CTE)  
1.3.1 Historical significance 
TBI resulting from blunt trauma to the head has been associated with disability since Martland 
described the cognitive impairment profile of boxers resulting from careers filled with concussive 
and/or sub-concussive injuries (Martland, 1928). This syndrome was termed ‘punch drunk’ or 
dementia puglistica (Millspaugh, 1937) due to its etiology stemming from the sport of boxing. 
Since Martland’s initial observations, further investigations regarding the specific mechanisms by 
which TBI can result in disability have been conducted. Notably, a similar pathology is now known 
to arise from repetitive head injury acquired during involvement in other professional sports, such 
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as American football, hockey, and martial arts (Funk, Rowson, Daniel, & Duma, 2012; Gessel, 
Fields, Collins, Dick, & Comstock, 2007; Rabadi & Jordan, 2001), and from single blast injuries 
as observed in military veterans (Miller, 2012). The presence of dementia puglistica in contexts 
other than those of repetitive head injury in boxing warranted a shift in the nomenclature describing 
this condition to chronic traumatic encephalopathy (CTE) so as to be in inclusive of this variable 
etiology (Critchley, 1957).  
1.3.2 Neuropsychiatric symptoms of traumatic brain injury (TBI) and CTE 
TBI is clinically associated with numerous cognitive and behavioural deficits both acutely and 
chronically following injury. The most commonly observed acute symptoms following TBI 
occurring within three months of injury and includes headaches, dizziness, fatigue, nausea, and 
sleep disturbances (McCrory et al., 2009; Petraglia, Maroon, & Bailes, 2012). in a survey of 
symptoms one month following a moderate TBI,  numerous emotional disturbances were 
observed, including apathy, loss of motivation, anxiety/tension, and difficulty controlling emotions 
once expressed (Paniak et al., 2002). A study of college football players examined acutely 
following TBI revealed the presence of cognitive symptoms, including neuropsychological deficits 
in cognitive processing and verbal memory. These symptoms were found to resolve within seven 
days following injury (McCrea et al., 2003).  
In some instances, the neuropsychological effects of TBI persist chronically. In CTE, there 
is an insidious progression of cognitive and behavioural dysfunction that can be observed over the 
course of decades. The earliest symptoms typically manifest as issues with attention, concentration 
and memory (Millspaugh, 1937), which correspond to the first of three stages of deterioration as 
described by Corsellis, Bruton, and Freeman-Browne (1973). This is followed by symptoms of 
social instability, amnesia, and the engagement in erratic behaviours. In the third and most 
progressed stage of the illness, patients may meet full diagnostic criteria for dementia and may 
also display gait disturbances (Corsellis, Bruton, & Freeman-Browne, 1973). Another severe 
neuropsychological feature of progressed CTE is heightened suicidality (reviewed in Wortzel, 
Shura, & Brenner, 2013), which has prompted considerable public concern regarding the long-
term risks associated with participation in contact sports.  
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1.3.3 Neuropathological features of CTE 
Initial gross neuropathological analysis of CTE brains revealed significant atrophy in many 
cortical regions including frontal, parietal, and temporal, but not occipital regions. In advanced 
stages of CTE, atrophy within hippocampal and entorhinal cortex was also noted (Corsellis et al., 
1973), accompanied by dilation of the lateral ventricles (case studies explored by McKee et al., 
2009). 
CTE is a tauopathy with neurofibrillary pathology being a frequent neuropathological 
finding present in  (McKee et al., 2015). Importantly, the tau pathology observed in CTE is 
neuropathologically distinct from that of Alzhemier’s disease in two major ways. Firstly, whereas 
Alzheimer’s tau pathology is observed diffusely throughout the neuroaxis; neurofibrillary tangles 
in CTE are observed in perivascular regions and are particularly abundant within the depths of 
cortical sulci (Geddes, Vowles, Nicoll, & Révész, 1999; Geddes, Vowles, Robinson, & Sutcliffe, 
1996). Secondly, we have shown that insoluble tau protein from CTE brains contain all six 
isoforms in contrast to the PHF tau triplet motif observed in Alzheimer’s disease (Moszczynski et 
al., 2018). These findings suggest that although both Alzhemier’s disease and CTE share some key 
neuropathological features, they are distinct tauopathies and thus might involve separate 
biochemical processes which then drive a common tau-mediated neurodegeneration.  
1.3.4 TBI as a risk factor for other neurodegenerative conditions 
Intriguingly, a large proportion of individuals who have post-mortem diagnosed CTE have a 
comorbid Alzheimer’s disease, Parkinson’s disease, or motor neuron disease (MND), such as ALS. 
A large post-mortem neuropathological study of 142 confirmed CTE cases showed that 15 
(10.56%) had a comorbid MND and another 15 (10.56%) had comorbid Amyloid-β pathology 
suggestive of Alzheimer’s disease. Of the remaining 112 individuals studied, 23 (16.20%) had a 
comorbidity with another neurodegenerative disease – Parkinson’s disease (PD), Lewy body 
dementia (LBD), frontotemporal dementia (FTD), or multiple diseases – and 89 (62.68%) had no 
comorbidity (McKee et al., 2015). Another series of investigations found that between 4-6% of 
CTE patients displayed a motor phenotype consistent with ALS (Mez et al., 2017). This is elevated 
when compared to the incidence of ALS in the general population, which is estimated to be 
approximately 2 per 100,000 (0.0002%; Worms, 2001).  These collective findings suggest that 
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individuals who have suffered neurotrauma possess a significantly greater risk of developing a 
neurodegenerative tauopathy and resultant cognitive impairment than those without brain injury. 
Therefore, studying the mechanisms by which TBI can contribute to the development of CTE may 
also increase our understanding of how tau-mediated neurodegeneration progresses in other 
neurodegenerative conditions.  
1.3.5 Animal models for studying TBI 
Although CTE has been described as a TBI-induced neurodegenerative tauopathy, the precise 
mechanisms by which TBI may result in a progressive neurodegenerative condition are not well 
characterized. Understanding this pathogenesis requires model systems that recapitulate the 
biological features of CTE, including the neuropathological observation of perivascular 
hyperphosphorylated tau, neurofibrillary tangles, and increases in GSK3β activity. Animal models 
have been developed to allow for the examination of the neuropathological consequences of TBI. 
The simplest experimental injury model is the controlled weight drop, also referred to as 
the Marmarou method (Foda & Marmarou, 1994; Marmarou et al., 1994). It is the most frequently 
utilized method of administering a TBI to rodents. In this paradigm, an anesthetized rodent is 
secured with the rodent’s head at the base of a vertical track. A weight is then placed on the track 
from a specified height and allowed to fall onto the head by gravity, administering an injury that 
is proportional to the mass of the object and the height at which it is released (Piper, Thomson, & 
Miller, 1996). As an optional manipulation to this paradigm, a small midline incision can be made 
at the top of the head of the rodent to expose the skull, onto which a small circular disk is glued 
with dental cement to ensure direct energy transfer to the underlying skull. This method of injury 
is associated with diffuse axonal injury, particularly within fibers of the corpus callosum 
(Kallakuri, Cavanaugh, Ozaktay, & Takebayashi, 2003), and bilateral microvascular damage 
(Foda & Marmarou, 1994). One such experiment utilizing the weight drop method in a wild-type 
mouse model found that injured rodents had an elevation in the cis conformer of pThr231 and 
oligomeric tau as early as one week following TBI (Albayram et al., 2017).  
Fluid percussion injury is another method commonly implored when investigating TBI in 
a wide variety of animals, including rodents. In this method, the dura of an anesthetized animal is 
deformed by a fluid pressure pulse transmitted through a craniotomy (McIntosh, Noble, Andrews, 
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& Faden, 1987). Unlike the weight drop TBI model in which a weight must be dropped vertically 
down onto the animal’s head, fluid percussion can be conducted on lateral positions on the brain 
(McIntosh et al., 1989), allowing for unilateral injury. One study utilizing this model demonstrated 
the formation of numerous pathologic tau protein phospho-epitopes including: AT100 and AT8, 
and tau oligomers within 24 hours of injury (Hawkins et al., 2013). Another similar investigation 
found that the phosphorylation of GSK3β and protein kinase B (PKB) was elevated within three 
hours and continued until 24 hours post-injury (Shapira et al., 2007). Fluid percussion injury, 
which is designed to replicate human concussion, results in increases in tau kinase phosphorylation 
acutely and is associated with the accumulation of aberrantly phosphorylated tau protein and 
oligomers.  
Controlled cortical injury (CCI) is an injury model frequently used in rodents whereby the 
dura of an anesthetized animal is impressed by a small metal piston through a craniotomy (Dixon, 
Clifton, Lighthall, Yaghmai, & Hayes, 1991). This method of experimental TBI utilizes a 
mechanical pneumatic impactor that allows for accurately controlling the velocity, depth, and 
dwell time of the injury. Given that these parameters can be controlled for accurately in this model, 
it has been extensively utilized in the examination of biomolecular changes associated with tau 
protein pathology following TBI (Tran et al., 2012; Tran, Sanchez, Esparza, & Brody, 2011; Yu, 
Zhang, & Chuang, 2012; Zanier et al., 2018). Our lab has recently found that administering CCI 
on adult female rats results in the formation of pThr175 tau neurofibrillary pathology as well as 
increases in pTyr216 GSK3β three months following injury, thereby recapitulating two key 
hallmarks of endogenous tauopathy (Moszczynski et al., 2018). 
1.4 Amyotrophic Lateral Sclerosis (ALS) 
1.4.1 Overview 
ALS is an adult-onset neurodegenerative disorder characterized by the loss of upper, lower and 
cranial nerve motor neurons (Zinman & Cudkowicz, 2011). The degeneration of these structures 
phenotypically results in numerous motor signs, including muscular spasticity, fasciculations, 
exaggerated stretch reflexes, and progressive muscle weakness frequently resulting in paralysis. 
The incidence of ALS in Western populations is approximately 2 in 100,000  (Worms, 2001), and 
prognosis is poor, usually resulting in death by aspiration pneumonia due to respiratory muscular 
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dysfunction 2-5 years following diagnosis (Wijesekera & Nigel Leigh, 2009). Currently, the 
mainstay pharmacological treatment for ALS is a drug called Riluzole, which provides a modest 
extension of life by approximately 2-3 months relative to that of placebo (Miller, Mitchell, Lyon, 
& Moore, 2003). The lack of effective treatments for ALS highlights the need to better understand 
the etiology, pathogenesis, and heterogeneity of this disease to identify better pharmacological 
targets, which may be used to treat those afflicted with this devastating condition.  
1.4.2 Etiology and epidemiology  
The etiology of ALS varies considerably, with 5-10% of cases associated with a defined genetic 
variant (familial ALS, fALS), and 90-95% of cases being sporadic in nature (sALS) with no 
identified genetic cause. Neuropathologically, ALS is associated with the dysmetabolism of 
various proteins that form neuropathological inclusions primarily in the motor neurons of the 
affected individual, including misfolds of transactive response DNA-binding protein of 43 
kilodaltons (TDP-43) (Furukawa, Kaneko, Watanabe, Yamanaka, & Nukina, 2011; Guo et al., 
2011; Nonaka et al., 2013; Tsuji et al., 2012), superoxide dismutase 1 (SOD1) (Chia et al., 2010; 
Grad et al., 2014; Münch, O’Brien, & Bertolotti, 2011), and fused in sarcoma/translocated in 
liposarcoma (FUS/TLS) (Nomura et al., 2013). 
The mechanisms underlying sALS are not yet fully understood. Exposure to specific 
environmental toxins has been historically documented to result in an ALS phenotype as in the 
hyperendemic foci of Guamanian ALS in the Western Pacific. Of note, this variant of ALS displays 
a widespread tauopathy throughout the neuraxis and within the spinal cord in a number of patients 
(Hirano, Arumugasamy, & Zimmerman, 1967). Various epidemiological investigations have 
spawned numerous hypotheses regarding potential environmental stressors which may initiate the 
neurodegenerative processes of ALS, including those involving TBI. Consistent with this, research 
from our lab has identified the presence of tau protein pathology within the spinal cords of patients 
with comorbid CTE-ALS (Moszczynski et al., 2016). Increasing our understanding of the full 
breadth of etiological agents resulting in an ALS phenotype will aid in the identification of novel 
pharmacological targets to prevent or slow disease progression, and understanding the 
heterogeneous clinical phenotypes observed in this disease will allow for better controlled clinical 
trials.  
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1.4.3 ALS frontotemporal spectrum disorders (ALS-FTSD) 
Although initially believed to be a disorder of exclusive motor dysfunction, more recent 
investigations have shown that approximately 50-60% of individuals with ALS possess a 
concurrent frontotemporal spectrum disorder (FTSD) (Elamin et al., 2011; Hudson, 1981; 
Montuschi et al., 2015; Oh et al., 2014). Strong and colleagues (2009, 2017) defined diagnostic 
criteria to accurately describe the different variants of ALS that also contain a frontotemporal 
syndrome, termed ALS-FTSD. Some individuals with ALS will also present with a concurrent 
frontotemporal dementia (ALS-FTD) meeting the Neary or Hodge’s criteria (Hodges & Miller, 
2001; Neary et al., 1998). Other affected individuals may not fully meet the criteria for FTD, but 
will nonetheless display detectable cognitive impairment (ALSci) or behavioural impairment 
(ALSbi). ALSci is defined as the diagnosis of ALS with additional evidence of impaired social 
function, executive and/or language dysfunction. Apathy is the most common behavioural 
symptom identified in patients with ALSbi with some reports suggesting it can be identified in up 
to 70% of individuals with the disease (Lillo, Mioshi, Zoing, Kiernan, & Hodges, 2011; Witgert 
et al., 2010). Other symptoms associated with the ALSbi variant include disinhibition, egocentric 
behaviour, and changes in grooming or dietary habits. Patients may display features of both ALSci 
and ALSbi, with their merged diagnostic category being ALS with cognitive and behavioural 
impairment (ALScbi), also described as a dysexecutive syndrome. Finally, there exists a variant 
whereby individuals with ALS display a concurrent dementia not specified by the other mentioned 
criteria: ALS-Dementia. The presence of cognitive or behavioural impairment in individuals with 
ALS is an important feature when making predictions regarding patient prognosis in that 
individuals with cognitive or behavioural impairment demonstrate a significant decreased 
survivorship when compared to those with isolated ALS, with one study showing a decrease in 
survivorship by 12 months (Elamin et al., 2011). Other forms of ALS have been categorized based 
on their co-occurrence with other neurological conditions, including ALS with Alzheimer’s 
disease (ALS-AD), and ALS with CTE (ALS-CTE). 
Neuropathologically, ALS-FTSDs have been associated with the dysmetabolism of TDP-
43, with evidence of aggregates in cortical regions associated with FTD (Arai et al., 2006; 
Neumann et al., 2006). The breadth of neuropathological features common between ALS and FTD 
has led to the hypothesis that these diseases might exist on two ends of a disease spectrum (Ferrari, 
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Kapogiannis, Huey, & Momeni, 2011). Within this spectrum are a series of disorders which, 
although heterogeneous in clinical presentation, share related pathology.  
1.4.4 Tau protein dysmetabolism in ALSci 
Although typically associated with the dysmetabolism of TDP-43 and the presence of TDP-43 
pathology, there is an abundance of evidence supporting that tau protein dysmetabolism is 
observed in ALS (reviewed in Moszczynski, Hintermayer, & Strong, 2018). Within our cohort of 
ALSci patients, there are numerous case reports and experimental studies that have identified a 
tauopathy. Initial neuropathological observations of ALSci patients identified tau-immunoreactive 
neuronal and glial cytoplasmic inclusions within the anterior cingulate cortex of affected 
individuals (Yang, Sopper, Leystra-Lantz, & Strong, 2003). This tauopathy was demonstrated to 
be distinct from that of Alzheimer’s disease, and most similar to that of CTE, consisting of pThr175 
and pThr231 tau present in all six tau protein isoforms within sarkosyl-insoluble fractions, tau 
immunoreactive neurofibrillary tangles, and increases in the expression of active GSK3β 
(Moszczynski et al., 2018b; Moszczynski et al., 2016; Strong et al., 2006; Yang et al., 2008). The 
dysmetabolism of tau protein in ALS has since been replicated by a separate group (Stevens, 
Guthrie, van Roijen, Halliday, & Ooi, 2019). Considering that 90-95% of ALS cases are sporadic 
in nature, exploring the varied conditions under which an ALS/ALSci-phenotype may develop will 
contribute to our understanding of disease pathogenesis and potentially lead to the identification 
of therapeutic interventions for those affected.  
1.5 Rationale  
1.5.1 The pathogenicity of pThr231 and pThr175 tau  
It is a well-established principle that phosphorylation of tau protein at the Thr231 residue is a critical 
event in tau cytoplasmic inclusion formation (Alonso et al., 2010; Cho & Johnson, 2003; 
Moszczynski et al., 2014; Moszczynski et al., 2016). Phosphorylation of tau at Thr231 
electrostatically moves the N-terminal domain away from the C-terminal domain, making the 
protein more vulnerable to further phosphorylation by additional kinases (Lin et al., 2007), and by 
forming a salt bridge with Arg230 which directly inhibits microtubule interaction (Schwalbe et al., 
2015). These factors collectively contribute to an increase in the aggregation propensity of tau 
proteins in neurons and suggests the importance of this epitope as an early harbinger of tauopathy.  
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The tau pThr175 epitope was recently identified in the inclusions of individuals with ALSci 
and CTE (Moszczynski, McKee, Strong, & Strong, 2018). In contrast to the pThr231 epitope which 
is frequently seen in healthy adults, the pThr175 epitope appears to be much more specific to the 
disease state (Moszczynski et al., 2017; Strong et al., 2006; Yang, Ang, & Strong, 2005). Research 
from our lab has investigated the pathogenicity of this epitope in vitro and demonstrated that the 
pseudophosphorylation of tau protein at this residue results in increases in fibril formation and 
enhanced caspase-3 cleavage (Gohar et al., 2009). Intriguingly, transfecting cells with this 
pseudophosphorylated tau protein construct was sufficient for increasing the expression of active 
GSK3β in vitro, and inhibition of GSK3β was shown to abolish increases in fibril formation in this 
model (Moszczynski et al., 2014). Importantly, increases in fibril formation required 
phosphorylation at Thr231, indicating that this pseudophosphorylated construct likely led to the 
activation of GSK3β, which then phosphorylates tau at Thr231 resulting in fibril formation. 
Subsequent experiments have further demonstrated the importance of the pThr175 epitope in the 
disease state, describing its presence and association with active GSK3β in a rodent TBI model 
(Moszczynski et al., 2018a). Additionally, research from our group has demonstrated an increase 
in tau protein pathology following AAV9 delivery of a Thr175 pseudophosphorylated tau protein 
construct to rat hippocampus (Moszczynski et al., 2018). These data suggest that the presence of 
the pThr175 tau epitope is sufficient for inducing changes in kinase activity, which are known to 
drive tauopathy, and that these changes can be experimentally induced in vivo with rodent TBI. 
The mechanisms, however, by which pThr175 tau is capable of initiating changes in active GSK3β 
and subsequent fibril formation in these models are not currently well understood.  
1.5.2 Scope of the current thesis 
The aim of the current thesis is to better understand the role of pThr175 tau in the formation of tau 
protein inclusions. To satisfy this aim, I have conducted both in vitro and in vivo experiments to 
propose a mechanism of tau pathogenesis and have tested this mechanism against an in vivo model 
for experimentally inducing tauopathy.  
I will investigate a potential mechanism by which pThr175 tau might initiate increases in 
active GSK3β expression, and will test this mechanism experimentally using our in vitro model 
system (as described in Gohar et al., 2009). I will be testing the postulate that the pathologic 
phosphorylation of tau at Thr175 either induces, or is associated with, disruption of tau tertiary 
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structure resulting in increased PAD exposure. I predict that the previously observed pThr175-
mediated increases in active GSK3β expression and fibril formation in this model are dependant 
upon increased exposure of the tau PAD in our pseudophosphorylated tau protein construct, and 
the PAD-PP1 interaction (Figure 1.5).  
I will utilize our previously described in vivo rodent TBI-induced tauopathy model to 
investigate the sequential nature of tau pathogenesis. Specifically, I will assess tau phosphorylation 
at Thr175, exposure of the PAD, and fibril formation, as well as changes in kinase activity at 
numerous timepoints spanning four months following TBI. Neuropathological assessment and 
biochemical assays will be utilized to characterize the sequential nature of tauopathy pathogenesis 
to identify acute changes that contribute to fibril formation.  
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Figure 1.5 Taken from Moszczynski, Hintermayer, and Strong (2018). Schematic representation 
of the hypothesized mechanism by which phosphorylation of tau at Thr175 causes increased GSK3β 
activity. pThr175 tau results in conformational change in which the phosphatase-activating domain 
(PAD) is exposed. PAD exposure interacts with protein phosphatase 1 (PP1) activating it and 
increasing activity. PP1 then dephosphorylates GSK3β at the inhibitory Ser9 residue, thereby 
increasing GSK3β activity, resulting in the unloading of cargo from kinesin and inhibition of FAT. 
Activated GSK3β then phosphorylates tau protein at other residues, including Thr231, resulting in 
the formation of tau fibrils. 
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1.5.3 Hypothesis and aims 
Hypothesis:  The phosphorylation of tau protein at Thr175 is associated with increases in PAD-
exposure, which contributes to the development of tau protein fibrils following TBI. 
Aims: 
1)  Examine the contribution of PAD exposure in pThr175 tau-mediated GSK3β activation and 
fibril formation, and; 
2) Characterize and describe the development of tau protein pathology over time in a rodent 
model of TBI-induced tauopathy.  
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
PROCEDURES AND METHODOLOGY 
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2.1 Tau protein constructs and cloning 
All tau protein constructs were based on  the EGFP-C1 vector (Clontech) and encoded the 2N4R 
human tau protein isoform, as previously described (Gohar et al., 2009; Moszczynski et al., 2015). 
Tau protein constructs were: unmodified at Thr175 (Thr175WT), Thr175Ala mutant (pThr175 
deficient), or Thr175Asp mutant (to mimic phosphorylation at Thr175; described in Gohar and 
colleagues, 2009). It is important to note that there are limitations in utilizing phosphomimic 
proteins in this manner. The mutation of Thr to Asp introduces a negatively charged carboxylate 
ion which is meant to recapitulate the electrostatic effect from the addition of a point negative 
charge of a phosphate added at this site. However, Asp and Glu residues are much smaller than 
phosphorylated Thr and Ser residues, and in some experiments this method has failed to 
demonstrate functional outcomes resembling phosphorylation (Dai et al., 2013; Zheng et al., 
2003). Additionally, the use of an eGFP-tag on a protein of interest can have effects on protein 
structure, stability, and half-life within the cell that might then affect the dependant variables under 
study (Sokolovski, Bhattacherjee, Kessler, Levy, & Horovitz, 2015). These limitations are 
important to consider when interpreting the results of studies that utilize eGFP-tagged 
phosphomimetic proteins. All mutant tau protein constructs utilized are listed in Table 2.1.  
A Thr175Asp construct lacking the tau PAD (aa 1-18) was generated (Thr175Asp delPAD). 
The Thr175Asp tau protein construct was subjected to polymerase chain reaction (PCR) with 
primers (Sigma) excluding the tau PAD (forward: 5’-ATA TCT CGA GCT GGG TTG GGG GAC 
AGG AAA G-3’, reverse: 5’-TAT TGG ATC CTC ACA AAC CCT GCT TGG CCA GGG A-3’). 
Following amplification, DNA fragments were resolved on a 1% agarose gel in TAE buffer, and 
the band containing the tau protein fragment purified using the Nucleospin Gel Purification Kit 
(TakaraBio) as per manufacturers protocol. Purified DNA was then cloned into pGEM-T-Easy 
vector (Promega) according to manufacturers instructions. The resulting pGEM-Thr175Asp 
delPAD construct, and the vector EGFP-C1 were digested with BamHI and XhoI restriction 
endonucleases (Invitrogen), separated by agarose gel electrophoresis and isolated as above. 
Thr175Asp delPAD tau fragments were ligated into EGFP-C1 vector and then transformed into 
DH5α competent E. coli (Invitrogen) using the heat shock method (ice 30 minutes, 42°C for 45 
seconds with plasmid DNA, cooled on ice 2 min). Transformed cells were allowed to recover for 
one hour at 37°C with shaking in Lauria Broth (LB) and then were streaked onto kanamycin 
selective agar plates. Individual colonies were grown at 37°C for 16 hours and were then picked 
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to be grown overnight in kanamycin selective LB. Following overnight growth, E. coli containing 
the desired plasmid were lysed and DNA was isolated using MiniPrep Kit (Invitrogen) as per 
manufacturers instructions. Constructs were confirmed by DNA sequencing. 
Since the function of the tau PAD has been shown to be inhibited by phosphorylation at 
the Tyr18 residue (Kanaan et al., 2012), tau protein constructs containing mutations at this site were 
created by site-directed mutagenesis (Lightning QuikChange site-directed mutagenesis kit II; 
Agilent) as per manufacturers instructions. Thr175WT, Thr175Ala, and Thr175Asp tau protein 
constructs were subjected to site-directed mutagenesis Tyr18 residue (TAC) to Phe18 (forward: 5’-
AT CAC GCT GGG ACG TTC GGG TTG GGG-3’, reverse: 5'-CCC CAA CCC GAA CGT CCC 
AGC GTG AT-3') preventing phosphorylation at this site (Thr175WT-Tyr18Phe, Thr175Ala-
Tyr18Phe, and Thr175Asp-Tyr18Phe) or Glu18 (Forward: 5’-AT CAC GCT GGG ACG GAA GGG 
TTG GGG GA-3’, reverse: 5’-TC CCC CAA CCC TTC CGT CCC AGC GTG AT-3’) mimicking 
phosphorylation at this site (Thr175WT-Tyr18Glu, Thr175Ala-Tyr18Glu, and Thr175Asp-Tyr18Glu). 
As per manufacturer’s protocols, the parent strand DNA was then subjected to Dpn I restriction 
enzyme digest, and the remaining nonlinearized DNA containing mutated plasmid was 
transformed into DH5α competent E. coli, grown, isolated, and sequence confirmed as above.  
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Table 2.1 Tau protein constructs utilized 
Tau Protein Construct 
Mutation 
Thr175 PAD 
WT  WT Tyr18WT 
Thr175Ala  Ala Tyr18WT 
Thr175Asp Asp Tyr18WT 
Thr175Asp delPAD Asp Deleted 
Thr175Asp-Tyr18Phe Asp Tyr18Phe 
Thr175Asp-Tyr18Glu Asp Tyr18Glu 
 
Table 2.1 List of eGFP-tagged tau protein constructs utilized in the current thesis, representing 
full-length (2N4R, 441aa) human tau. Unmutated residues are denoted as wild type (WT). Residue 
modifications were made at the Thr175 residue to either prevent (Thr175Ala) or mimic (Thr175Asp) 
phosphorylation, as well as the Tyr18 residue to prevent (Tyr18Phe) or mimic (Thr18Glu) 
phosphorylation. An additional tau protein construct pseudophosphorylated at Thr175 but that 
lacked the PAD was also created (Thr175Asp delPAD). 
 
 
 
 
 
 
 
 
 
 
32 
 
2.2 Cell culture and transfection 
Human embryonic kidney (HEK293T) cells were cultured on 100mm petri dishes in Dulbecco’s 
modified eagle medium (DMEM; ThermoFisher) supplemented with 10% fetal bovine serum 
(FBS; ThermoFisher) and 0.5% penicillin-streptomycin antibiotic (ThermoFisher). HEK293T 
cells were utilized in the current thesis for their ease of transfectability, and to remain consistent 
with our previous experiments (Gohar et al., 2009). It is important to note that HEK293T cells are 
non-neuronal, and the use of a neuronal cell line (i.e. Neuro2A, SH-SY5Y) might be a more 
suitable model for studying neuronal cytoskeletal dynamics or neuronal stress response. Cells were 
incubated and allowed to proliferate at 37°C and 5% CO2. Transfections for all experiments were 
conducted in opti-MEM reduced serum media (ThermoFisher) with Lipofectamine-2000 
transfection reagent (ThermoFisher) according to manufacturers instructions. Following 
transfection, half of the media was replaced with supplemented DMEM (as above) for 24 hours to 
allow the transfection to run to completion, after which all media was replaced with supplemented 
DMEM. 
2.3 In vitro protein sample preparation and Western blotting 
Cells were washed with ice cold PBS, pelleted, and then lysed on ice with lysis buffer (20mM Tris, 
2mM EGTA, 5mM EDTA, 30mM NaF, 60mM β-glycerophosphate, 20mM Na-pyrophosphate, 
1mM Na-orthovanadate, 1mM DTT, 1% Triton-100X) with protease inhibitor cocktail (cOmplete, 
Roche) and phosphatase inhibitor (5µM pepstatin A). Protein lysate was quantified using BioRad 
DC protein quantification assay in a 96-well plate as per manufacturer’s protocol. Samples 
containing 20µg of protein were mixed with sample buffer (50% glycerol, 125mM Tris-HCl pH 
6.8, 4% SDS, 0.08% Bromophenol blue, 5% β-mercaptoethanol) and heated to 100°C for 4 minutes 
to denature proteins.  
Samples were then separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Following separation, proteins were transferred for one hour onto 
nitrocellulose membrane in cooled transfer buffer (25mM Tris, 192mM glycine, 20% MeOH). 
Following transfer, membranes were washed with TBS-T buffer (50mM Tris, 150mM NaCl, 1% 
Tween-20, pH 7.4) and were incubated at room temperature on rotating platform for one hour in 
10% bovine serum albumin (BSA) in TBS-T to block non-specific binding sites. Primary antibody 
was then added according to the titers specified in Table 2.1 and were incubated for one hour at 
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room temperature. Following primary incubation, membranes were washed, blocked as above, and 
then probed with a horseradish peroxidase-conjugated secondary antibody (1:3000 titer) for one 
hour at room temperature. Membranes were washed and signal visualized using enhanced 
chemiluminescence (ECL) reagent (Perkin-Elmer). Western blots were imaged, and densitometry 
was conducted using Image Lab (Bio-Rad) software package. All experiments were conducted in 
triplicate.  
2.4 Protein Immunoprecipitation  
Cells were washed with ice cold PBS, pelleted, and then lysed on ice with lysis buffer (20mM Tris, 
2mM EGTA, 5mM EDTA, 30mM NaF, 60mM β-glycerophosphate, 20mM Na-pyrophosphate, 
1mM Na-orthovanadate, 1mM DTT, 1% Triton-100X) with protease inhibitor cocktail (cOmplete, 
Roche) and phosphatase inhibitor (5µM pepstatin A). Protein lysate was quantified using BioRad 
DC protein quantification assay in a 96-well plate as per manufacturer’s protocol.  
A 1.0mg aliquot of cell lysate was subjected to pansorbin (S. aureus) immunoprecipitation. 
A mixture of 20μL pansorbin, 1mg of cell lysate, and 1μg of capture antibody was diluted to 1.0mL 
with ice-cold lysis buffer and was incubated for one hour at room temperature with constant 
rotation to allow the capture of proteins of interest. As a control, generic IgG was utilized as a 
capture antibody. Immunoprecipitated product was pelleted at 14,000 RPM for 10 minutes at 4°C, 
and the supernatant was removed and placed in a clean tube for the examination of equal loading. 
Immunoprecipitated product was washed three times with 1.0mL of ice-cold lysis buffer, pelleting 
the pansorbin-protein complex by centrifugation as above, discarding the resulting supernatant. A 
final wash and centrifugation step were conducted with PBS. The resultant washed 
immunoprecipitation product as well as the supernatant from the immunoprecipitation reaction 
was denatured by heating in 40μL of sample buffer (50% glycerol, 125mM Tris-HCl pH 6.8, 4% 
SDS, 0.08% Bromophenol blue, 5% β-mercaptoethanol) to 100°C for 4 minutes to denature 
proteins. Prepared immunoprecipitation samples were separated by SDS-PAGE and examined by 
Western blotting procedure as above.  
2.5 Non-denaturing lysis conditions, native and dot blotting 
Cells were washed with ice cold PBS and pelleted by centrifugation. Cells were then lysed by 
sonication in PBS with protease inhibitor cocktail (cOmplete, Roche) and phosphatase inhibitor 
(5µM pepstatin A) on ice, four times at 40kHz 10 seconds each. Lysates were mixed with non-
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denaturing sample buffer (5mM Tris, 38.33mM glycine, 10% glycerol, 0.0001% Bromophenol 
blue) and immediately run on 7.5% native PAGE gels containing no SDS, followed by transfer to 
nitrocellulose membrane and Western blotting as above. For dot blotting, a 1µg aliquot from each 
sample of cell lysate was dotted directly onto nitrocellulose membrane and allowed to air dry for 
10 minutes. Membranes were then subjected to probing with antibodies, washing and detection as 
described above.  
2.6 In vitro Fibril Counting Assay 
Transfected HEK293T cells were plated into 35mm confocal dishes and examined for the presence 
of fibrils after expressing tau protein constructs for 72 hours. The presence of dense curvilinear 
GFP-tau-positive fibrils in these cells was assessed in a blinded manner using a Leica SP8 confocal 
microscope with a 63x objective. Each dish was subdivided into quadrants and a representative 
population of eGFP-tau expressing cells were counted in each quadrant. A minimum of 30 live 
cells were counted per dish, and the percentage of GFP positive cells with curvilinear fibrils was 
determined as conducted previously (Gohar et al., 2009; Moszczynski et al., 2015).  
2.7 Rodent Controlled Cortical Injury (CCI) 
All experimental protocols were approved by the University of Western Ontario Animal Care 
Committee (AUP #2017-135) in accordance with the policies established in the guide to Care and 
Use of Experimental Animals prepared by the Canadian Council on Animal Care. Rodents in the 
experimental group were exposed to controlled cortical injury (CCI). Adult female Sprague 
Dawley rats (~300g/~3 months old) were placed under isoflurane gas anesthetic (4% induction, 
1.5%-2.0% maintenance) so that bilateral toe pinch reflex was absent. Rodents were fixed in place 
using a stereotaxic apparatus and the surgical area was shaved and cleaned with soap, Betadine, 
and 70% ethanol. An anterior-posterior 3.0cm midline incision was made on the head of the rodent, 
and a craniotomy was performed using a 5mm trephine centered at stereotaxic coordinates: AP 
Bregma -4.0mm, ML 3.5mm from midline skull markings. A controlled cortical impactor was 
used to impress on the rodent dura with the following parameters: 2.0mm depth, 3.5m/s impact 
velocity, and 500ms dwell time. Following impact, bleeding was controlled using cotton swabs 
moistened with normal sterile saline (0.9% w/v NaCl), and the incision was sutured closed. Control 
animals were placed under anesthesia for a similar duration, but no incision or craniotomy was 
conducted. All animals were given 1.0 mg/kg slow-release buprenorphine analgesic 
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subcutaneously at the beginning of the procedure, and 1.0 mL of sterile saline for hydration at the 
end of procedure. Rodents were housed individually following the procedure for three days and 
were weighed daily, following which they were housed in pairs until time of euthanasia.  
2.8 Preparation of rodent brain lysates 
Rodents utilized for biochemical assays were euthanized by pentoparbitol overdose and 
transcardiac perfusion with room temperature heparin-saline mixture (0.9% w/v NaCl, 10U/mL 
Heparin (Sigma)). Brains were isolated rapidly, separated midsagittally into hemispheres, and snap 
frozen on dry ice, before being stored at -80°C until homogenization.  
At the time of homogenization, frozen brains were washed three times with ice cold 
phosphate buffered saline (PBS) and were sectioned into three segments relative to the injured 
region: rostral to injury (frontal regions), a middle section containing the injury (cortex and limbic 
structures), and caudal to injury (brainstem and cerebellum). Brain sections were processed using 
a tissue homogenizer for three cycles of 15 seconds each in lysis buffer (20 mM Tris, pH 7.0; 2mM 
EGTA; 5mM EDTA; 30 mM sodium fluoride; 60 mM β-glycerophosphate; 20mM sodium 
pyrophosphate; 1mM sodium orthovanadate; 1% Triton X-100) with protease inhibitor cocktail 
(cOmplete, Roche) and phosphatase inhibitor (5µM pepstatin A). Samples were then sonicated at 
40kHz four times (10 seconds each) on ice to shear nuclear DNA, and were spun at 90,000g using 
a Beckman ultracentrifuge in 6.0 mL heat sealed tubes to clear lipids and DNA from the 
homogenized solution. The resulting supernatant containing protein was aliquoted and quantified 
using the BioRad DC protein assay. Samples were stored at -20°C until utilized in Western blotting 
and immunoprecipitation experiments. 
2.9 Immunofluorescence Staining 
Rodents utilized for immunohistochemistry were euthanized by pentoparbitol overdose and 
transcardiac perfusion as above, followed by perfusion fixation with cold 4% paraformaldehyde. 
Brains were isolated rapidly, separated midsagittally into hemispheres, and maintained in 4% 
paraformaldehyde for 48 hours at 4°C. Isolated hemispheres were then sectioned coronally into 
approximately 2mm slices and dehydrated in 50% ethanol for one hour at RT, and then in 70% 
ethanol at 4°C overnight. Dehydrated brain sections were then processed and embedded in paraffin 
(Robarts Pathology Core Laboratory). Paraffin embedded blocks of rodent brain tissue were 
sectioned at 6µm onto glass slides. Sections were heated at 60°C for 30 minutes, and dewaxed by 
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submersion in a series of baths (xylenes - 15min, 1:1 xythenes:ethanol – 10min, 100%, 95%, 75%, 
and 50% ethanol, and distilled H2O – 5min each). Following dewaxing, antigen retrieval was 
conducted to expose antigens by heating slides to 120°C using a pressure cooker (2100 Retriever; 
Aptum Biologics, Southampton, UK) in citrate buffer (10 mM sodium citrate, 0.05% Tween 20, 
pH 6.0). For the examination of native epitopes and conformations of proteins, antigen retrieval 
steps were omitted. Slides were then incubated with blocking solution (5% bovine serum albumin, 
0.3% Triton-X 100 in PBS) for 30 minutes. Antibodies were diluted in blocking solution at the 
titers specified in Table 2.2 and slides were incubated overnight at 4°C. Slides were then washed 
with PBS, and then incubated with secondary antibodies in blocking solution (goat α mouse 
AlexaFluor 488, donkey α rabbit AlexaFluor 555) for 1 hour at room temperature. Tissue was then 
counterstained with Hoechst 33258 (Biotium) for 15 minutes at room temperature to visualize 
nuclei. Coverslips were placed with Immu-mount aqueous mounting media (ThermoFisher), and 
slides were visualized using an EVOS FL Auto2 fluorescence visualizing system, or a Leica SP8 
confocal microscope in a blinded manner to avoid bias.  
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Table 2.2 Antibody Titers Utilized 
Epitope 
Titer 
Organism Source (Catalogue #) 
Western IF 
pThr¹⁷⁵ tau 1:1000 1:1000 Rabbit 21st Century 
Tau-5 1:1000 n/a Mouse ThermoFisher (AHB0042) 
TNT1 1:180K 1:40K Mouse * 
GSK3β 1:10,000 n/a Mouse BD Biosciences (610201) 
pTyr²¹⁶ GSK3β 1:10,000 n/a Mouse BD Biosciences (612312) 
pSer⁹ GSK3β 1:1000 n/a Rabbit Abcam (ab107166) 
GFP 1:4000 n/a Rabbit Abcam (ab6556) 
GAPDH 1:4000 n/a Rabbit Abcam (ab9485) 
PP1 1:500 n/a Mouse Cell Signalling (2582) 
 
Table 2.2 Antibodies utilized in current experiments with specified titers for both Western blotting 
and immunofluorescence (IF) microscopy. * TNT1 antibody recognizing the tau protein PAD was 
generously donated by N. Kanaan, Michigan State University. 
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2.10 Rodent Acoustic Startle Response (ASR) and Pre-Pulse Inhibition (PPI) 
Startlebox testing was conducted on adult female Sprague Dawley rats prior to euthanasia at 7, 14, 
30, 45, 60, 90, and 120 days following procedure (TBI or Control). Startlebox testing was 
conducted over four days. On day 1, rodents were placed in clear plastic tubes, and placed on a 
platform within a Med Associates soundproof startle chamber. Rodents were acclimatized to a 
65dB white noise stimulus for a 5-minute period of time twice, with a four-hour rest in between 
acclimatization sessions. On day 2, rodents were acclimatized to the 65dB stimulus for 5-minutes 
once in the morning. In the afternoon of day 2, and input-output curve was determined by assessing 
ASR in response to stimuli of the following intensities: 75, 85, 100, 110, and 120dB. The input-
output curve was used to determine the appropriate gain to set the startle platform as to ensure 
proper recording of ASR within the range of the instruments utilized. The following startle range-
gain combinations were utilized in response to the 110dB stimulus: 0-500mV – 3.0 gain, 501-
1000mV – 2.0 gain, 1001-2000mV – 1.0 gain, >2000mV – 0.5 gain. On day 3, rodents were first 
acclimatized for 5 minutes as before. ASR was then determined by exposing rodents to 25 startle 
stimuli of 110dB in intensity. Rodents were then exposed to 50 trials of 110dB startle stimuli which 
were immediately preceded by pre-pulses 30 or 100ms, of intensities 75dB or 85dB. In all cases 
startle amplitude was assessed by mV readings resulting from compression of the startle platform.  
2.11 Statistical Analysis 
Statistical analysis of raw data utilized standard one-way analysis of variance (ANOVA) with 
Tukey LSD post-hoc assessment of specific effects. In cases where sphericity was violated on 
within-subjects variables, Greenhouse-Geisser degree of freedom corrections were utilized. Data 
values reported represent mean measure of central tendency with standard errors of the mean as a 
depicted measure of variance within the data. Significance was taken to be p<0.05. All statistical 
analyses were conducted utilizing SPSS (IBM, V23) software package, and graphs depicting data 
were created in Microsoft Excel (2018). Biological triplicates for each condition in each 
experiment was conducted unless otherwise specified. 
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Chapter 3 
EXPERIMENTAL SET 1 – THE ROLE OF THE N-TERMINAL 
PHOSPHATASE-ACTIVATING DOMAIN IN CYTOPLASMIC 
INCLUSION FORMATION IN VITRO 
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3.1 Introduction  
We have previously shown that cell expressing a tau protein construct pseudophosphorylated at 
the Thr175 residue (Thr175Asp) possessed an increased propensity to form fibrils in vitro when 
compared to wild-type (Thr175WT) and Thr175Ala tau (Gohar et al., 2009). Transfection of cells 
with this construct was associated with an increase in active GSK3β (pTyr216 GSK3β/Total 
GSK3β), a known tau kinase. Inhibiting GSK3β in this model – either by pharmacological 
inhibition or by shRNA knockdown – abolished the increases in fibril formation previously 
observed with this pseudophosphorylated mutant, as did preventing phosphorylation at the Thr231 
residue (Thr231Ala) (Moszczynski et al., 2015). The results from this study suggests that Thr175Asp 
tau protein causes increases in active GSK3β expression, which likely results in the further 
phosphorylation of tau at Thr231, thereby increasing the propensity of tau protein to form fibrils. 
This pathologic mechanism places the activation of GSK3β by Thr175Asp tau as a central factor in 
tau pathogenesis and can contribute to tau fibril formation. However, the mechanisms by which 
this pseudophosphorylated tau protein construct modulates GSK3β activity are currently unknown.  
The tau protein PAD consists of aa 2-18 on the N-terminus of tau, and is normally 
prevented from interacting with other proteins within the cell due to tau’s native global hairpin 
conformation (Jeganathan et al., 2006). However, an analysis of tau isolated from individuals with 
Alzheimer’s disease and CTE shows that, in the disease state, the PAD is aberrantly exposed 
(Combs et al., 2016). Intriguingly, deletion of exons 6-9 in the MAPT gene is associated with 
familial FTD and results in loss of the hinge region crucial for maintaining tau’s hairpin 
conformation and preventing interactions with other proteins in the cell. Exposure of the PAD is 
increased in tau protein filaments. When tau protein filaments with elevated PAD exposure are 
perfused into giant squid axoplasm, anterograde FAT in inhibited and the unloading of vesicles 
from kinesin occurs prematurely (Kanaan et al., 2011). PAD-mediated inhibition of FAT is 
dependant upon activation of PP1 which removes an inhibitory phosphate from Ser9 of GSK3β, 
thereby increasing its activity (Kanaan et al., 2011). Intriguingly, this effect can be eliminated by 
the pseudophosphorylation of tau protein at the Tyr18 residue – a Fyn kinase phosphorylation site 
– which potentially eliminates or reduces interactions with PP1 (Kanaan et al., 2012).  
The purpose of the current investigation is to determine the mechanism by which Thr175Asp 
tau protein increases GSK3β activity, which we have demonstrated is critical for fibril formation 
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in vitro. I hypothesize that the aberrant phosphorylation (or pseudophosphorylation) of tau protein 
at Thr175 is associated with conformational changes resulting in increased exposure of the tau PAD, 
thereby contributing to PP1-mediated activation of GSK3β and subsequent fibril formation. 
3.2 Results 
3.2.1 Thr175Asp tau induces changes in GSK3β phosphorylation status  
To study the effects of pseudophosphorylated tau protein constructs on the phosphorylation status 
of GSK3β in vitro, HEK293T cells were transfected with one of four eGFP-tagged constructs: 
EGFP-empty vector (‘eGFP’), Thr175WT, Thr175Ala, or Thr175Asp tau protein. First, the 
transfection efficiency of each eGFP-tagged tau protein construct was determined by assessing the 
percentage of cells expressing the construct by fluorescence microscopy 24 hours following 
transfection. One-way analysis of variance (ANOVA) was conducted to determine any significant 
differences in transfection efficiency and expression between conditions. The average transfection 
efficiency of these constructs was 79% and did not significantly differ between groups (p=0.433). 
Additionally, the expression of eGFP-tagged tau protein constructs was assessed between 
transfection conditions by Western blotting, revealing no significant differences in expression 
between transfection conditions (p=0.308, Figure 3.1). 
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Figure 3.1 Transfection efficiency and expression levels observed for the eGFP-tau constructs 
utilized in current experimental set. A) Transfection efficiency was determined by counting GFP-
tau positive cells relative to total number of cells using fluorescent microscopy (GFP positive 
cells/total cells * 100%). The average transfection efficiency was ~79%, with no significant 
differences between transfection groups (p=0.433). B) The expression of eGFP-tagged tau protein 
constructs was found to not differ between transfection conditions (p=0.308). The relative 
expression of our constructs was calculated from densitometric analysis of Western blots by the 
equation: GFP/GAPDH. Data values calculated were normalized to eGFP (not shown) for each 
biological replicate. Error bars represent standard errors of the mean (SEM). Each experiment was 
conducted in biological triplicate. 
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 The phosphorylation status of GSK3β was then assessed by Western blotting 72 hours 
following transfection. Consistent with our previous findings (Moszczynski et al., 2015), 
Thr175Asp tau transfected cells had an increase in active GSK3β – assessed as the ratio of pTyr216 
GSK3β/total GSK3β – relative to eGFP (p=0.003), Thr175WT (p=0.003), or Thr175Ala (p=0.001) 
(Figure 3.2). Upon assessing the phosphorylation status of the regulatory Ser9 residue of GSK3β 
(pSer9 GSK3β/total GSK3β), it was observed that Thr175Asp tau expression resulted in a decrease 
in abundance of this epitope relative to eGFP (p=0.044), Thr175WT (p=0.006), or Thr175Ala 
(p=0.016). This is consistent with the proposed model of PAD-mediated GSK3β activation. 
Therefore, transfection of this construct not only resulted in an increase in phosphorylation of the 
catalytic domain of GSK3β but was also associated with a reduction in inhibition of primed 
phosphorylation, thereby likely resulting in an increase of GSK3β activity in vitro.  
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Figure 3.2 The effect of pseudophosphorylated (Thr175Asp) tau on the phosphorylation status of 
GSK3β. A) Representative Western blot showing an increase in pTyr216 GSK3β and a decrease in 
pSer9 GSK3β for cells transfected with Thr175Asp tau. B) Densitometry results from Western 
blotting, representing the pGSK3β/Total GSK3β ratio. Data values calculated were normalized to 
eGFP (not shown) for each biological replicate. Error bars represent standard errors of the mean 
(SEM). Each experiment was conducted in biological triplicate. *p<0.05 compared to any of the 
other constructs.  
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3.2.2 Thr175Asp tau is associated with increases in accessibility of the PAD  
To test the hypothesis that phosphorylation of tau at Thr175 results in conformational changes to 
tau protein that increase PAD exposure, HEK293T cells were transfected with Thr175WT, 
Thr175Ala, or Thr175Asp tau constructs and were lysed in non-denaturing conditions 72 hours 
following transfection. It is important to note that the TNT1* antibody recognizes only exposed 
tau PAD and therefore allows for the differentiation between physiologic and pathologic 
conformations of tau protein in lysates (Kanaan et al., 2011; LaPointe et al., 2009). However, 
denaturing tau protein by exposing lysates to detergents, as is conducted in SDS-PAGE protein 
assays, increases the abundance of this conformation-specific epitope. Therefore, experiments 
utilizing the TNT1 antibody were conducted in non-denaturing conditions so as to preserve the 
native conformations of tau proteins. Non-denatured cell lysates were loaded onto a native PAGE 
gel and separated by electrophoresis. It was noted that a significant amount of PAD and GFP 
immunoreactivity was present at the top of the gel following electrophoresis, indicating that some 
proteins in the lysate had not moved into the native gel (Figure 3.3). Densitometric analysis 
revealed that the relative accessibility of the PAD was significantly elevated in Thr175Asp tau 
protein when compared to Thr175Ala tau (p=0.013) and approached significance when compared 
to Thr175WT (p=0.054). 
 
 
 
 
                                                             
* TNT1 antibody recognizing the tau protein PAD was generously donated by N. Kanaan, Michigan State 
University. 
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Figure 3.3 Native PAGE assessment of PAD exposure for the three eGFP-tagged tau protein 
constructs. A) representative native PAGE gel probed first for the tau N-terminal antibody (PAD; 
top panel; TNT1 antibody), and then reprobed for total GFP tag (GFP; bottom panel). B) 
Densitometry results from Western blotting. ‘Top’ denotes immunoreactivity that appeared to be 
present within the wells of the native gel, indicating that this protein entered neither the running 
nor stacking gels during electrophoresis. ‘Gel’ denotes immunoreactivity for bands of eGFP-
tagged tau protein that entered the native gel and were separated by electrophoresis. Error bars 
represent standard errors of the mean (SEM). Each experiment was conducted in biological 
triplicate. *p<0.05. 
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The presence of PAD and GFP immunoreactive bands at the top of the native gel is 
problematic when interpreting the results of the above densitometric analysis, as higher molecular 
weight complexes containing tau might not have completely transferred from the gel to the 
nitrocellulose membrane. If this transfer were not complete, the subsequent Western blotting 
analysis would not include all tau protein present in the cell lysate. To mitigate this problem, cell 
lysates prepared as above were analyzed by dot blot to examine all tau protein species present in 
the sample. A 1µg sample of each of the cell lysates was blotted directly onto a nitrocellulose 
membrane and assessed for PAD immunoreactivity relative to GFP by Western blotting procedure. 
It was found that relative PAD exposure was significantly increased in lysates possessing the 
Thr175Asp pseudophosphorylated tau protein construct compared to the Thr175WT and Thr175Ala 
tau protein constructs (p<0.001). 
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Figure 3.4 Dot blot assessing the accessibility of the PAD for non-denatured lysates from 
individual tau protein constructs. A) Representative dot blot probed first for tau exposed N-
terminal antibody (PAD/TNT1), and then probed for GFP as a measure of total eGFP-tau 
expression. B) Densitometry results from Western blotting. Results calculated as the densitometric 
ratio of exposed PAD to total eGFP-tau expression (PAD/GFP). Error bars represent standard 
errors of the mean (SEM). Each experiment was conducted in biological triplicate. ***p<0.001. 
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3.2.3 PAD deletion from Thr175Asp tau normalizes pTyr216  GSK3β levels 
To test the hypothesis that Thr175Asp tau mediated GSK3β activation is dependant upon increases 
in PAD exposure, HEK293T cells were transfected with a novel tau protein construct 
pseudophosphorylated at Thr175 but which lacked aa 1-18 comprising the PAD (Thr175Asp 
delPAD). Cells were lysed 72 hours following transfection as before and lysates were assessed by 
Western blotting for pTyr216 GSK3β. This analysis revealed that deleting the PAD from the 
Thr175Asp tau construct resulted in normalization of GSK3β phosphorylation status to baseline 
levels, suggesting that the observed activation of GSK3β may be PAD-mediated.  
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Figure 3.5 Figure demonstrating the effect of PAD deletion on levels of active GSK3β (pTyr216 
GSK3β/Total GSK3β) levels. A) Schematic representation of pseudophosphorylated Thr175Asp 
tau, and the novel construct which lacks the PAD (Thr175Asp delPAD) in hairpin conformation. 
The blue region represents the PAD, the green region represents proline-rich domain, red segments 
represent microtubule-binding domains. The locus of the Thr175Asp mutation is represented 
schematically as ‘D’ printed within the yellow circle.  B) Representative Western blot 
demonstrating specificity of the TNT1/PAD antibody, and the absence of PAD epitope in the novel 
construct (Thr175Asp delPAD). C) Representative Western blot showing that PAD deletion 
normalizes the increase in pTyr216 GSK3β observed when Thr175Asp tau protein is expressed. D) 
Densitometry results from Western blotting. Data values calculated were normalized to eGFP (not 
shown) for each biological replicate. Error bars represent standard errors of the mean (SEM). Each 
experiment was conducted in biological triplicate. ***p<0.001. 
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3.2.5 PAD mutation at Tyr18 reduces tau fibril formation in vitro 
The results from the previous section demonstrates that deleting residues 1-18 of tau protein that 
comprises the PAD results in normalization of GSK3β phosphorylation status in vitro. It has been 
previously demonstrated that phosphorylation – or pseudophosphorylation – of tau protein at the 
Tyr18 residue reduces PAD-mediated activation of PP1 and a subsequent increase in GSK3β in an 
ex vivo model of squid FAT (Kanaan et al., 2012). To assess the impact of phosphorylation at this 
residue in the current model, double mutant tau protein constructs were created which were 
pseudophosphorylated at Thr175 and were also either unphosphorylated, or pseudophosphorylated 
at the Tyr18 residue (Tyr18Phe, or Tyr18Glu, respectively) to either block or mimic phosphorylation, 
respectively, at this site. As such, a total of 5 constructs were utilized in this experiment (Table 
3.1).  
As before, preventing phosphorylation of Thr residues was accomplished by removing a 
methyl and hydroxyl group from the chiral carbon of the amino acid R-group, whereas mimicking 
phosphorylation at this residue was accomplished by substituting an Asp residue, which contains 
a large charged carboxylic acid group. Importantly, preventing phosphorylation at Tyr residues 
was accomplished by mutation to phenylalanine (Phe), which lacks the p-methoxyl group from the 
aromatic ring structure of Tyr. The mutation of Tyr to Phe instead of Ala was conducted as to 
preserve features of hydrophobicity and potential steric interactions that exist in the 
unphosphorylated Tyr residue. Pseudophosphorylating Tyr residues involved mutation to a 
glutamic acid (Glu) amino acid, which possesses a charged carboxylic acid group and is larger 
than the Asp residue used when mimicking phosphorylation of Thr residues.  
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Table 3.1 – List of eGFP-tau protein constructs utilized 
Plasmid Residue Mutation Thr175 Tyr18 
WT “wild type” WT WT 
Thr175Ala “unphosphorylated” Ala WT 
Thr175Asp “pseudophosphorylated” Asp WT 
Thr175Asp-Tyr18Phe Asp Phe 
Thr175Asp-Tyr18Glu Asp Glu 
 
Table 3.1 List of eGFP-tagged tau protein constructs utilized in the current experiment. Unmutated 
residues are denoted as wild type (WT). Residue modifications were made at the Thr175 residue to 
either prevent (Thr175Ala) or mimic (Thr175Asp) phosphorylation, as well as the Tyr18 residue to 
prevent (Tyr18Phe) or mimic (Thr18Glu) phosphorylation.  
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HEK293T cells were transfected with each of the three Thr175 tau constructs (Thr175WT, 
Thr175Ala, and Thr175Asp), in addition to our Thr175Asp-PAD double mutants (Thr175Asp-
Tyr18Phe, and Thr175Asp-Tyr18Glu). Cells were assessed for transfection efficiency by counting 
the number of GFP positive cells relative to total cells. Statistical one-way ANOVA revealed no 
significant differences between any of these groups (p=0.517, Figure 3.7A). Additionally, GFP 
levels were assessed to ensure there were no significant differences in expression between these 
groups. Densitometric analysis and statistical one-way ANOVA revealed no significant 
differences in expression between these constructs (p=0.264, Figure 3.7B,C).  
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Figure 3.7 Transfection efficiency and expression of eGFP-tau protein constructs used in 
experiments. A) Transfection efficiency was calculated by determining the percentage of cells 
expressing eGFP-tau 24 hours following transfection (GFP positive/total cells *100%). B) 
Representative Western blot assessing GFP levels and GAPDH loading control. C) Densitometric 
analysis of Western blotting. Values calculated as the ratio of GFP immunoreactivity relative to 
that of GAPDH loading control (GFP/GAPDH) for each biological replicate. Error bars represent 
standard errors of the mean (SEM). Each experiment was conducted in biological triplicate. 
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Our previous experiments showed that the inhibition of GSK3β by either shRNA or the 
use of pharmacological inhibitors  prevented increases in curvilinear fibril formation in Thr175Asp 
tau protein constructs (Moszczynski et al., 2015). To assess the effect of PAD mutation on GSK3β 
activation and resultant fibril formation in this model, a fibril counting assay was conducted on 
cells transfected with our tau protein constructs. This analysis revealed that  Thr175Asp tau protein 
expressing cells formed fibrils in a larger percentage of cells than Thr175WT (p<0.001) or Thr175Ala 
(p<0.001) tau protein, as previously described (Moszczynski et al., 2015). It is important to note 
that fibrils of Thr175Asp tau are qualitatively distinct from those of Thr175WT and Thr175Ala 
mutants, consisting of dense curvilinear tau fibrillar aggregates (Figure 3.7B). The additional 
mutation of tau protein at the Tyr18 residue to either prevent (Tyr18Phe, p=0.002) or mimic 
(Tyr18Glu, p<0.001) phosphorylation reduced fibril formation to baseline levels (Figure 3.7A). 
There was no difference in the number of cells that formed fibrils between Tyr18Phe and Tyr18Glu 
mutant tau protein constructs (p=0.160).  
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Figure 3.7 Live cell confocal imaging of fibril formation within eGFP-tau expressing cells. A) 
Bar graphs displaying the percentage of GFP-positive cells with fibrils. Fibril formation appears 
to be increased for tau pseudophosphorylated at Thr175, which is then reduced to baseline with the 
additional mutation of tau protein at Tyr18 to Phe or Glu. N=3/condition. ***p<0.001. ‘n.s.’ = not 
significant. B) Representative confocal images of fibril formation in eGFP-tau constructs. Fibrils 
found in Thr175WT and Thr175Ala mutants were thin and hairlike (red arrows) and formed in few 
cells. Fibrils formed in Thr175Asp mutant tau expressing cells were dense and curvilinear in 
morphology (white arrows). The additional mutation of Tyr18 within the PAD to either Phe or Glu 
decreased the percentage of cells with curvilinear fibrils, but in some cells curvilinear fibril 
morphology was still observed, as displayed in the Thr175Asp-Tyr18Glu mutant. Scale bars = 25μm. 
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3.2.6 Mutation of the tau N-terminus interferes with PAD-PP1 binding 
The results obtained in the previous section demonstrate that both mutations to prevent or mimic 
phosphorylation at the Tyr18 residue resulted in decreases in resultant fibril formation. We 
investigated the possibility that both of these mutations interfered with the interaction between 
exposed PAD and PP1 in this model. To assess the influence of PAD mutation on PAD-PP1 
binding, a co-immunoprecipitation experiment was conducted, in which the three Thr175Asp 
constructs (Thr175Asp, Thr175Asp-Tyr18Phe, Thr175Asp-Tyr18Glu) were pulled down with 
pansorbin-bound GFP antibody. Resultant pelleted fractions were then denatured and separated on 
SDS-PAGE and Western blotting was conducted to assess PP1 levels (Figure 3.8A). Preliminary 
analysis revealed no significant effect of tau construct expressed on the PAD-PP1 interaction 
(p=0.781). It was noted that values between biological replicates of this experiment varied 
considerably (Figure 3.8B), potentially due to batch effects when conducting the lysis and 
immunoprecipitation steps involved in this experiment. However, it was noted that within each 
replicate, the same trend was observed, with Tyr18 mutation resulting in a reduction in PP1 pulled 
down with eGFP-tau. To control for differences between biological replicates, the data from each 
biological replicate were normalized to Thr175Asp tau values. Following this adjustment, this 
experiment revealed that all three tau protein constructs had some binding between eGFP-tagged 
tau and PP1, but this interaction was significantly reduced for Tyr18Phe (p=0.025) and Tyr18Glu 
(p=0.015) mutants (Figure 3.8C).  
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Figure 3.8 Co-immunoprecipitation of eGFP-tagged tau lysates, captured with GFP antibody and 
probed for PP1. A) Representative Western blot showing a reduction in PAD-PP1 binding when 
the PAD is mutated to prevent (Thr175Asp-Tyr18Phe) or mimic (Thr175Asp-Tyr18Glu) 
phosphorylation within the PAD. IgG lane represents Thr175Asp tau lysate precipitated with anti-
rabbit IgG antibody. Supernatant fractions were loaded onto an SDS-PAGE gel and run as loading 
controls probed for GAPDH. B) Densitometry representing PP1 precipitated with eGFP-tagged 
tau when controlling for loading ((PP1/GFP)/GAPDH). The y-axis is split at 0.10 AU (dashed line) 
to aid in visualizing trends shared between each biological replicate. The numerical scale for both 
y-axes is linear. Each biological replicate is represented as a separate coloured line. Variability in 
raw values between replicates is large, with no significant main effect of tau construct expressed 
on PAD-PP1 binding. C) Densitometry representing PP1 precipitated with eGFP-tagged tau after 
normalizing to Thr175Asp for each biological replicate. PAD-PP1 binding is significantly reduced 
with both Tyr18 mutations. Error bars represent standard errors of the mean (SEM). Each 
experiment was conducted in biological triplicate. *p<0.05. 
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Chapter 4 
EXPERIMENTAL SET 2 – MODELING TAU PROTEIN FIBRIL 
FORMATION IN RESPONSE TO TBI IN VIVO 
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4.1 Introduction 
Experimental set 1 demonstrated that Thr175Asp pseudophosphorylated tau protein expression 
result in an increase in GSK3β activity and tau fibril formation in vitro. Results from those 
experiments suggest that the phosphorylation of Thr175 associates with increases in accessibility of 
the tau PAD, leading to GSK3β activation via tau’s interaction with PP1. The aim of Experimental 
Set 2 is to examine the formation of pThr175 tau pathologic fibrils in a rodent model of TBI, and to 
assess the potential correlates of this pathology with increases in the accessibility of the PAD.  
We have previously shown that administering a single TBI to adult female Sprague Dawley 
rats results in the formation of pThr175 tau fibrils and increases in active GSK3β by three months 
following injury (Moszczynski et al., 2018b). To examine the translational nature of our in vitro 
findings to this model of TBI-induced tauopathy, a time course analysis was conducted. Injured 
and control rodents were either given TBI or analgesia on T0 and were sacrificed at various time 
points following injury (1, 3, 5, 7, 10, 14, 21, 30, 45, 60, 90, and 120 days) for either tau-
immunohistochemistry (IHC) for pathology studies or for kinase expression analyses.  
4.2 Behavioural Deficits Following TBI 
Sensory gating is the process by which the brain modulates its sensitivity to various stimuli to 
selectively process and respond to incoming sensory information. Sensorimotor gating is a 
phenomenon in which sensory gating is used to determine the amplitude of a reflexive response. 
Deficits in sensory gating have been well documented in a variety of neurological and psychiatric 
conditions, including schizophrenia (Braff & Geyer, 1990; Dawson, Hazlett, Filion, Nuechterlein, 
& Schell, 1993), post-traumatic stress disorder (Meteran et al., 2019; Neylan et al., 1999), and TBI 
and concussion (Kumar et al., 2005; Papesh et al., 2019). The acoustic startle response (ASR) is a 
motor response in rodents evoked by an acoustic startle stimulus. An assessment of sensorimotor 
gating can be made by analyzing pre-pulse inhibition (PPI) of ASR in rodents, and this is 
accomplished by preceding a startle stimulus with a low intensity pre-pulse stimulus. PPI is a 
measure of the integrity of limbic and hindbrain circuitry in rodents (Bakshi & Geyer, 1998; 
Rohleder et al., 2016), and was conducted on rats at time points 7, 14, 30, 45, 60, 90, and 120 days 
following TBI to verify the presence of an injury. 
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4.2.1 Sensorimotor gating is impaired acutely following TBI 
To assess the impact of our TBI on rodent sensorimotor gating, PPI of ASR was experimentally 
determined by leading a 110dB startle stimulus with a 75dB pre-pulse that preceded the startle 
stimulus by either 30 or 100ms (Figure 4.1). A repeated measure analysis of variance (ANOVA) 
was conducted to examine if there was an impact of TBI on PPI ASR in this model by setting ISI 
as a within-subjects factor with two levels (30ms, 100ms) and Condition (Control, TBI) and 
Timepoint (7, 14, 30, 45, 60, 90, 120 days) as between-subjects factors. This omnibus analysis 
showed a main effect of Condition (p<0.001) and a significant Condition*Timepoint interaction 
(p=0.035), indicating that the impact of TBI on PPI was dependant on the Timepoint assessed. 
There was no main effect of Timepoint in the omnibus analysis (p=0.171). There was also a main 
effect of ISI (p=0.011) indicating that the degree of PPI was dependant on the duration of time 
separating the pre-pulse and startle stimuli. ISI was not found to interact with either TBI Condition 
(p=0.335) or Timepoint (p=0.772).  
To elucidate the locus of the significant Condition*Timepoint interaction, a series of 
independent samples t-tests were conducted to compare TBI and Control rodents at each timepoint, 
and with each ISI separately. For 30ms ISI, TBI resulted in a significant reduction in PPI seven 
days following injury (p=0.018), but not any other timepoint (Figure 4.1A). This analysis was 
repeated for a 100ms ISI, revealing that injured rats demonstrated a reduced PPI at seven (p<0.001) 
and 30 (p=0.033) days following TBI, but not at any other timepoint (Figure 4.1B).  
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Figure 4.1 TBI reduces PPI of ASR in the acute phase following injury. A) Results from PPI of 
ASR in response to a 75dB pre-pulse stimulus with 30ms ISI. B) PPI of ASR in response to 75dB 
with 100ms ISI. All data values display mean percent reduction in startle to a 110dB startle 
stimulus. Error bars display standard errors of the mean (SEM). N=6/condition/timepoint. 
*p<0.05, **p<0.01, ***p<0.001, ‘n.s.’ = not significant. 
65 
 
4.3 Neuropathological and Biochemical Consequences of TBI 
Neuropathologically, TBI is associated with tau immunoreactive neuronal cytoplasmic inclusions 
and fibrils immunoreactive for numerous pathologic tau epitopes, including pThr231, tau oligomers 
(T22) (Hawkins et al., 2013), tau aggregates (AT8), and pThr175 (Moszczynski et al., 2018a). 
However, the sequential phosphorylation events to tau protein which occur following TBI that 
result in fibril formation are not well characterized.  
Experimental Set 1 demonstrated that the pseudophosphorylation of tau at Thr175 results an 
increase in PAD exposure which then is associated with an increase in expression of active GSK3β. 
It is well-established that increases in GSK3β activity are associated with TBI, and contribute to 
tauopathy in a wide range of neurodegenerative conditions by phosphorylating tau at the Thr231 
residue, contributing to inclusion formation (Beurel et al., 2015; Cho & Johnson, 2004; Hooper et 
al., 2008). Therefore, to characterize the development of pThr175 tau protein fibrils in vivo, we first 
conducted immunohistochemical studies to examine the presence and relationships of pThr175 tau 
and exposed PAD following TBI. Immunohistochemical investigations were focused on the 
injured region of cortex, and the underlying fields of hippocampus (Figure 4.2). We then conducted 
a mass phospho-kinase screen (Kinexus Proteomics) to identify kinases that are differentially 
regulated following TBI in this model.   
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Figure 4.2 Composite light microscope images showing TBI brain (3 days post-injury) and 
uninjured contralateral cortex stained with hematoxylin and eosin (H&E). The injury area is clearly 
visible, beginning within the cortex and extending to the underlying hippocampus and lateral 
ventricular zones. Abbreviations: Hippocampus (CA1, CA2, CA3), CC = corpus callosum. Images 
taken with a 10X objective (Olympus BX45; Center Valley, PA) prior to digital stitching with 
Adobe Photoshop to form the composite shown.  
 
 
 
 
 
 
 
 
67 
 
4.3.1 pThr175 tau formation is an early event following TBI and associates with 
PAD exposure 
To better understand the sequential changes to tau protein following TBI which contribute to tau 
pathogenesis and inclusion formation, a time course analysis was conducted on injured rodent 
brains using immunofluorescence microscopy. Injured and control rodent brains were double 
immunolabeled for pThr175 tau and exposed PAD (TNT1) in native conditions and were 
qualitatively assessed for their presence, morphological characteristics and distribution within the 
injured region of the tissue (Figure 4.3).  
Minimal immunoreactivity for either pThr175 tau or exposed PAD was observed in control 
uninjured rat brains within the injured region. It was found that 1 day following injury, punctate 
staining for both epitopes was observed primarily in the soma of neurons in the damaged region. 
Immunoreactivity for pThr175 tau colocalized well with PAD exposure. Notably, PAD exposure 
was not observed in the absence of pThr175 tau staining supporting our hypothesis that pThr175 tau 
may associate with PAD exposure in the early phases of developing tauopathy following TBI. By 
3 days following TBI, a large increase in both pThr175 and PAD immunoreactivity was observed 
within cortical neurons in the injured region, again primarily localized within the soma. At 5 days 
following TBI, immunoreactivity for both epitopes appeared to begin to extend into axonal 
processes of neurons, remaining colocalized with some apparent neurofibrillary tangle formation 
observed by 10 days following TBI, immunoreactive for only pThr175 and absent for PAD. At 60 
days following TBI, numerous dense aggregated structures immunoreactive for pThr175 tau are 
observed within neurons in the injured cortex, with minimal immunoreactivity for exposed PAD 
observed (Figure 4.3). The use of antigen retrieval methods greatly increased the immunoreactivity 
for exposed PAD in a subsequent experiment (Figure 4.4A), demonstrating the importance of 
avoiding these methods in the current analysis.
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Figure 4.3 Fluorescent double immunolabeling of rat brain sections for pThr175 tau (red) and tau 
PAD exposure (green) observed by confocal microscopy. Minimal immunoreactivity for both 
epitopes is observed in uninjured rodents (Control). Within the injured cortex, pThr175 tau 
immunoreactivity is evident by 1 day following TBI and colocalizes with PAD exposure (purple 
arrows). PAD immunoreactivity increases and co-localizes with pThr175 tau completely in the 
soma at 3 days. By 5 days, immunoreactivity for both epitopes extend to neuronal processes. By 
10 days following TBI pThr175 tau immunoreactivity is greatly increased in neuronal processes in 
fibrillary structures and PAD immunoreactivity is reduced (white arrows). At 30 days following 
TBI numerous pThr175 fibrils are observed in cortical neurons, with minimal PAD 
immunoreactivity. By 60 days, fully formed pThr175 tau fibrils are present which lack the PAD. 
White scale bars = 50µm, yellow = 10µm. 
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4.3.2 Immunoreactivity for PAD does not co-localize with pThr175 tau in late-
tangle development 
Intriguingly, dense fibrils immunoreactive for pThr175 but lacking immunoreactivity for the tau 
PAD were evident near severely damaged tissue from 7 days following TBI (Figure 4.3). Since it 
has been previously documented that tau protein cleavage events occur during neurofibrillary 
tangle formation (Flores-Rodríguez et al., 2015), the possibility that the observed PAD-negative 
pThr175-positive inclusions contain N-terminally truncated tau proteins was explored.  
Firstly, fluorescent double immunolabeling on injured rodent tissue was conducted as 
before but with the addition of antigen retrieval methods (to expose potentially hidden epitopes in 
the tissue) to examine whether these pThr175 tau inclusions possess the tau N-terminus comprising 
the PAD, or if this epitope is simply buried in developed fibrils. This analysis revealed that pThr175 
tau inclusions remained PAD-negative following antigen retrieval (Figure 4.4A). The absence of 
PAD immunoreactivity in these dense pThr175 tau protein fibrils supports the hypothesis that an 
N-terminal truncation event might have occurred. 
An immunoprecipitation experiment was conducted to determine whether or not PAD-
negative pThr175 tau protein fragments are present at 120 days following TBI, as this is the latest 
timepoint in the current experiment and is expected to be associated with the most developed 
pathology. Since we have demonstrated the presence of PAD-negative dense fibrils, it was 
hypothesized that tau proteins, which are pThr175 tau-positive and PAD negative, would be of high 
molecular weight. Lysates from injured and control rodents were first captured with a pThr175 tau 
antibody. Immunoprecipitated product was denatured in sample buffer by heating to 100°C for 4 
min to expose all antigens and was then assessed by Western blotting probing first for pThr175 tau 
and then for the tau N-terminus. This analysis demonstrated the presence of many high molecular 
weight (~100-250 kDa) pThr175 immunoreactive tau bands which were absent for the tau N-
terminus (Figure 4.4B). Due to methodological limitations, we were not able to assess both of 
these epitopes on monomeric tau protein species (47-63kDa), due to cross reactivity of our 
secondary antibodies with the FC regions of our capture antibody. These results collectively 
suggest that the tau N-terminus containing the PAD is truncated in late-stage tau protein fibrils in 
vivo.  
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Figure 4.4 pThr175 tau immunoreactivity occurs in the absence of PAD immunoreactivity in late-
stage tau protein fibrils. A) Fluorescent double immunolabeling of injured tissue for pThr175 tau 
and PAD with (Denatured) and without (Native) antigen retrieval 30 days post-TBI examined by 
confocal microscopy. Tau fibrils present in native conditions with the absence of PAD 
immunoreactivity (white arrows). Following protein denaturation, pThr175 tau fibrils remained 
PAD negative. White scale bars = 40µm, yellow scale bars = 10µm. B) Western blots for 
immunoprecipitation experiment. ‘Probe’ denotes the antibody visualized on Western blot. 
‘Capture’ denotes the antibody used for immunoprecipitation. Numerous bands immunoreactive 
for pThr175 tau were observed in both TBI and control rat lysates 120 days post-TBI. Lysates were 
also probed for TNT1 (PAD) to assess the presence of the tau N-terminus consisting of aa 2-18. 
Black arrows indicate band regions for significant pThr175 immunoreactivity. Numerous bands 
present in Western blotting for pThr175 tau are absent for PAD immunoreactivity. 
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4.3.2 pThr175 tau co-localizes with PAD immunoreactive hippocampal aggregates 
and fibrils in vivo 
We have shown above that there is an association between pThr175 tau and PAD exposure, which 
appears to dissociate at later timepoints following TBI when tau PAD immunoreactivity is lost. 
This pathology was observed to be more severe, and perhaps most rapidly progressive in the 
damaged tissue immediately in the injured region. To assess the possibility that PAD exposure 
persists in regions more distal to the site of injury, our analysis was extended to the underlying 
hippocampus. Neuronal aggregates with distinct puncta contained within the cytoplasm, as well as 
extended immunoreactivity within neuronal processes were observed up to the latest timepoint 
assessed (120 days) following TBI (Figure 4.5). This finding suggests that although in more 
severely injured regions of the cortex PAD immunoreactivity was absent in densely formed fibrils, 
regions underlying and more distal to the injured region demonstrate pathology with persistent 
PAD exposure, potentially contributing to more latent fibril development in these regions. 
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Figure 4.6 pThr175 (red) and PAD (green) immunoreactive subcortical neurons. A) CA1 
hippocampal ghost tangle present in rat brain 90 days following TBI immunoreactive for both 
pThr175 tau and exposed PAD (white arrows). B) Neuronal processes in a CA3 hippocampal neuron 
120 days following rat TBI. Aggregated tau species are present within cell body, with 
immunoreactivity for both epitopes extending into axonal processes. White scale bars = 30µm, 
yellow = 10µm. 
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4.4.3 pTyr216 GSK3β levels were not modified following TBI 
To determine the effect of TBI on increases in the expression of active GSK3β (pTyr216 GSK3β/ 
Total GSK3β levels), Western blotting was conducted on rodent lysates isolated from the injured 
sections of TBI and control rats. Lysates were probed first for pTyr216 GSK3β, and then were 
stripped and reprobed for total GSK3β. The ratio of pTyr216 GSK3β/Total GSK3β was determined 
by densitometry, and a univariate ANOVA was conducted with Condition (TBI or Control) and 
Timepoint (d1-120) as fixed factors. Surprisingly, this analysis revealed no main effects of TBI on 
the levels of pTyr216 GSK3β (Figure 4.6A, B). 
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Figure 4.7 Analysis of pTyr216 GSK3β levels in rodent brain homogenates following TBI. A) 
Representative Western blots of rodent lysates containing the injured or control left hemispheres 
of rats. Western blots were probed first for pTyr216 GSK3β, and then were stripped and reprobed 
for Total GSK3β. B) Densitometry results for Western blots, representing the levels of active 
GSK3β (pTyr216 GSK3β/Total GSK3β). Each experiment was conducted in biological triplicate. 
All data values for active GSK3 β expression were normalized to the average of control animals 
within each timepoint. Error bars represent standard errors of the mean (SEM). All comparisons 
were not significant (‘n.s.’). 
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4.4.4 Phospho-kinase screening identified numerous kinases modified by rodent 
TBI 
The above findings suggest that the post-translational modifications to tau protein following TBI 
occur in a sequential nature. Importantly, each phosphorylation site on tau protein contains a 
unique epitope, and is thus recognized and preferentially phosphorylated by different kinases, 
frequently within the proline-directed kinase family (Hanger et al., 1998). To model the relative 
abundance of active kinases in vivo following TBI, a large kinase epitope screen was conducted 
(Kinexus Proteomics, British Columbia). Biological triplicates from injured and control rodents 
within each timepoint were pooled into a single sample (n=12/condition) and were assessed for 
the abundance of phosphorylated and unphosphorylated kinase epitopes to estimate changes in 
kinase activity following TBI. We were particularly interested in correlating increases in 
phosphorylated tau species with increases in specific kinases to potentially determine which 
kinases are responsible for certain tau phosphorylation events. This epitope screen identified that 
the phosphorylation of numerous kinases are modulated by TBI and their total and phosphorylated 
levels fluctuate over time. A heatmap graphically depicting these findings is displayed in Figure 
4.7A, and scatterplots representing these data are presenting in Figure 4.7B. 
Although the heatmap in Figure 4.7 represents phosphorylated kinase levels from a single 
pooled triplicate sample at each time point, some general observations can be made. Firstly, it is 
clear that various kinases are differentially reactive to TBI. Specifically, ERK, JNK, and p38 
appear to be generally increased acutely following TBI in this experiment, whereas Fyn, AK1 and 
GSK3β levels appear to be decreased. Intriguingly, the levels of phosphorylated kinases fluctuated 
rhythmically following the time course of TBI, likely reflecting a multifaceted signalling cascade 
in acute and prolonged stress from TBI (Figure 4.7B).  
From section 4.3.1, we see that pThr175 tau is present one day following TBI and is absent 
in controls. One important question is then which kinase might be responsible for the 
phosphorylation of tau protein at this residue. At 1 day following TBI, this kinase screen identified 
numerous candidates for phosphorylating tau at Thr175, including: c-Jun N-terminal kinase 1 
(JNK1), GSK3β, p38, and AKT1. The relevance of these targets is discussion further in section 
5.3 – Future Directions.  
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Figure 4.7 A) Heat map representing time course of phosphorylation profile of kinases in rodent 
injured cortex following TBI. All data values were normalized to control uninjured rodent brain 
within each time point. Each timepoint contained a single TBI and control sample of a pooled 
triplicate. B) Scatter plots representing fluctuations in the phosphorylation levels of numerous 
kinases following TBI. Data values were taken from the heatmap displayed in ‘A’ and correspond 
to the relative abundance of phospho-epitopes (pKinase/Total Kinase).   
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5.1 Discussion of Thesis 
5.1.1 Aims and objectives  
The phosphorylation of tau protein at the Thr175 residue is a pathological event associated with 
numerous tauopathies including Alzheimer’s disease, CTE, and ALSci (Moszczynski et al., 2017), 
and is not present in healthy aged individuals (Yang et al., 2005). The specificity of 
phosphorylation of tau at Thr175 to the disease state has prompted the investigations present within 
the thesis, and primarily concern the potential for this tau protein modification to initiate or 
contribute to tau pathogenesis: the process by which tau cytoplasmic inclusions and fibrils are 
formed and cause cytotoxicity.  
There were two main objectives that were set for the current master’s thesis. Firstly, we 
aimed to better understand the pathogenicity of our Thr175Asp tau protein construct from a 
mechanistic perspective. Specifically, our previous findings demonstrated that transfection of a 
Thr175Asp pseudophosphorylated tau protein construct in vitro resulted in increases in expression 
of active GSK3β, which subsequently increased fibril formation via an unknown mechanism. We 
hypothesized that increases in GSK3β activity results from conformational changes to tau protein 
that aberrantly expose the PAD, an N-terminal domain recently characterized for it’s ability to 
initiate GSK3β-mediated inhibition of FAT in the squid axon (Combs et al., 2016; Kanaan et al., 
2011). This mechanism was applied to the pathogenicity of our Thr175Asp mutant tau protein 
construct (Figure 1.1). Initial experiments demonstrated that transfecting cells with a Thr175Asp 
tau protein construct resulted in an increase in pTyr216 GSK3β, as well as a reduction in pSer9 
GSK3β levels, and showed that PAD deletion prevented increases in the expression of active 
GSK3β. Dot blotting confirmed the elevation of PAD exposure in Thr175Asp relative to Thr175WT 
and Thr175Ala tau. Further, mutation of Tyr18 of the tau PAD to either prevent (Tyr18Phe) or mimic 
(Tyr18Glu) phosphorylation reduced GSK3β-dependant fibril formation in vitro. These results 
were supplemented with a co-immunoprecipitation experiment, showing that both PAD mutations 
at Tyr18 interfered with the PAD-PP1 interaction in vitro. These results support that mimicking 
phosphorylation of tau at Thr175 results in the aberrant increase in exposure the N-terminus of tau 
protein containing the PAD, and this exposure appears to be critical for fibril formation via the 
PAD interacting with PP1. Additionally, mutating the Tyr18 residue within the PAD disrupts the 
PAD-PP1 interaction, and this correlates well with reductions in fibril formation. Experimental 
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Set 1 therefore provides evidence supporting the role of aberrant increases in PAD exposure in the 
pathogenicity of Thr175Asp tau, resulting in increases in active GSK3β expression and the 
formation of tau protein fibrils in vitro. 
The second objective of this work was to assess the association between phosphorylation 
at Thr175 and PAD exposure in an in vivo model of TBI-induced tauopathy. It was demonstrated in 
vitro that pseudophosphorylation of tau at Thr175 was associated with increases in PAD exposure, 
and this finding was also demonstrated in vivo by the colocalization of these epitopes acutely 
following TBI in injured cortical tissue. Specifically, pThr175 tau immunoreactivity colocalized 
with exposed PAD throughout the early stages of fibril development, occurring from 1-30 days 
following TBI. The presence of exposed PAD in early-stage neurofibrillary tangles has been 
documented in a small number of CTE and Alzheimer’s disease patient samples (Kanaan et al., 
2016). Experimental Set 2 is the first in vivo time course analysis that has investigated increases 
in PAD exposure throughout the development of tau fibrils. These data in conjunction with the 
findings from Experimental Set 1 suggest that phosphorylation of tau at Thr175 is an early event 
following TBI, and associates with increases in the accessibility of the PAD that drive the 
development of tau protein fibrils.  
5.1.2 The activation of PP1 by interaction with tau 
The activity of PP1 is regulated by the formation of heterodimeric complexes with regulatory units 
(termed ‘PP1-interacting proteins’; PIPs) which determine the localization of the PP1 within the 
cell and it’s target (Wera & Hemmings, 1995). The quantity and diversity of PIPs is exceptionally 
large, including approximately 200 proteins (Heroes et al., 2013). PIPs can bind to the catalytic 
site of PP1 (termed PP1c) and regulate its activity. However, many PIPs possess the same RVXF 
(where ‘X’ is a nonspecific amino acid) binding motif that binds to PP1c, and thus this lone binding 
event cannot account for the diversity of PP1 targets. Recently, researchers have investigated the 
complexity of PIPs interaction with PP1, and have demonstrated that a single PIP might have 
multiple ‘docking sites’ on PP1 (Bollen, Peti, Ragusa, & Beullens, 2010). In this way, each PIP 
has a unique series of binding sites on PP1, which modulate its activity and targets within the cell. 
This barcode-like regulation better accounts for the diversity and specificity of PP1 activity within 
the cell.  
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The specific binding sites of tau protein with PP1 have not yet been identified. One 
experiment identified tau protein as a direct binding partner for PP1, involved in the localization 
of PP1 to microtubules under physiological conditions (Liao et al., 1998). Since tau protein PAD 
exposure is a pathologic event, the primary binding site of tau-PP1 is likely not within the PAD, 
but rather the PAD may bind PP1 on a docking site, aberrantly increasing it’s activity or changing 
it’s target to pSer9 GSK3β. Importantly, the structural effects of PIP-PP1 binding are what regulate 
the targets activity of the enzyme complex. Therefore, the tau-PP1 complex which is formed with 
aberrantly phosphorylated tau protein might have a unique conformation, directing it to the 
phosphorylated Ser9 residue of GSK3β. Although the total inhibition of PP1 using Inhibitor-2 has 
been demonstrated to eliminate pathologic PAD-mediated inhibition of FAT in squid axon 
(Kanaan et al., 2011), the nonspecific inhibition of PP1 in vivo may have detrimental effects on an 
organism due to the large number and diversity of PP1 targets. However, if inhibitors specific to 
the conformation of PP1c within the pathologic PAD-PP1 complex can be synthesized, one could 
selectively inhibit PP1’s activation of GSK3β associated with the aberrant phosphorylation of tau 
and the development of fibrils, as demonstrated in Experimental Set 1. This unique solution would 
require a detailed structural analysis of the PAD-PP1 complex, and the development of small 
molecule inhibitors that fit within the catalytic domain of this complex. Theoretically, the 
therapeutic potential of such a drug would involve both preventing the progression of tau protein 
fibril formation, and simultaneously reducing PAD-mediated neurotoxicity. Additionally, 
assuming such small molecule inhibitors had sufficient specificity to this pathologic PAD-PP1 
complex, this treatment option would likely possess fewer major side effects since PAD-mediated 
inhibition of FAT by PP1 is a non-physiologic process.  
5.1.3 Tau PAD exposure may precipitate a pathological positive-feedback loop 
Previous reports have demonstrated that PAD exposure is elevated in tau fibrils and that exposed 
PAD is sufficient for the pathological inhibition of FAT. The results from the current thesis have 
extended these findings to show that tau PAD exposure might also contribute to the development 
of tau fibrils via PP1-mediated activation of GSK3β. Therefore, these collective findings suggest 
that early modifications to tau protein, which contribute to PAD exposure might also initiate a 
pathologic positive-feedback loop, whereby fibrils consisting of aberrantly phosphorylated tau 
protein with increased PAD-exposure are continuously formed. This positive feedback loop is then 
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initiated with a pathologic event resulting in increases in PAD exposure, with the current thesis 
suggesting that the phosphorylation of tau at Thr175 is sufficient in initiating this process.  
5.1.4 Tau protein truncation products as a source of accessible PAD  
Intriguingly, numerous investigations have reported caspase-3 truncation of the tau N-terminus as 
an event associated with the formation of tau fibrils both in vivo and in vitro(Means et al., 2016; 
Rissman et al., 2004). However, the result of such truncation products being introduced to neurons 
is not fully understood. The truncation of the PAD could be argued to serve a neuroprotective role, 
with N-terminal truncation resulting in the degradation of the PAD thereby reducing PAD-
mediated neurotoxicity. If this is true, then the activation of proteases to truncate tau protein might 
occur in response to the hyperphosphorylation of tau protein. However, if tau fragments containing 
the PAD are not subsequently degraded and remain biologically active in the cell, cleaving this 
domain from tau protein may exacerbate neurotoxicity via the mechanisms demonstrated in the 
current thesis. Therefore, the result of tau N-terminal truncation may depend on if the truncation 
products are degraded once formed or remain biologically active in the cell.  
5.1.5 The truncation of tau protein as an important pathologic process 
Although the current thesis focused mainly on the phosphorylation of tau protein, tau protein 
truncation was also observed. In vivo experiments utilizing rodent TBI to induce pathological tau 
fibril formation demonstrated that these cleavage events occur throughout the development of 
pThr175 tau fibrils and are absent in fully formed fibrils. The cleavage of tau protein in pathologic 
conditions is a well-documented phenomenon, with specific tau cleavage events occurring in both 
early and late-stages of fibril development in Alzheimer’s disease (Flores-Rodríguez et al., 2015). 
The hypothesized roles of tau protein truncation events vary considerably, with suggestion that tau 
fragmentation may contribute to neurotoxicity by both a loss of physiological tau protein function 
in the cell – resulting in microtubule destabilization - and/or a toxic gain of function – such as the 
aberrant inhibition of FAT via PAD exposure (Combs et al., 2016).  
Tau protein truncation products may be subject to proteasomal degradation soon after 
cleavage. However, if a truncation event results in a tau protein fragment being formed which 
contains the PAD, then it is possible that this PAD fragment may initiate the hyperphosphorylation 
of tau protein via the PAD-PP1-GSK3β pathway demonstrated in Experimental Set 1. In tau 
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protein’s hairpin conformation, the C-terminal end interacts with the PAD and inhibits the 
interactions between the PAD and PP1, and thus removal of the C-terminus may aberrantly expose 
the PAD.  
  Intriguingly, previous in vitro work from our lab has documented a tau truncation product 
only present in our Thr175Asp eGFP-tagged tau protein construct with a molecular weight of ~37 
kDa. A 6-year-old Western blot containing this fragment was restored and reprobed for the TNT1 
epitope to revealing that this low molecular weight fragment contains the PAD (Figure 5.1). 
Although the topic of tau protein truncation was not extensively explored in this thesis, these 
preliminary results indicate that truncation events resulting in the formation of PAD-
immunoreactive tau fragments occur in response to pseudophosphorylation of tau protein at Thr175. 
The role of tau protein truncation events which result in pathologic PAD exposure is therefore a 
potential area to extend our current investigations concerning our pathologic Thr175Asp tau protein 
construct. 
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Figure 5.1 Western blot demonstrating the fragmentation of Thr175Asp eGFP-tau protein construct 
in Neuro2A cell lysates. Western blot on the left was probed for GFP immunoreactivity 
(visualizing the eGFP tag) by Dr. Alexander Moszczynski in 2013 (not published). Western blot 
on the right shows that same blot stripped and reprobed for the tau N-terminus (PAD). The 
fragment of interest (black arrow) is both GFP and PAD immunoreactive.  
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5.1.6 Post-translational modification to Tyr18Phe tau mutants may mediate 
impaired PAD-PP1 interaction and reductions in fibril formation  
In sections 3.1.4-3.1.5, the effect of mutation of tau protein at Tyr18 within the PAD on fibril 
formation was assessed in vitro. The Tyr18Phe mutation was meant to functionally prevent 
phosphorylation at this site, since it has been demonstrated that either phosphorylation by Fyn or 
pseudophosphorylation (Tyr18Glu) at this site prevents PAD-mediated GSK3β activation and 
inhibition of FAT in the squid axon (Kanaan et al., 2012). Based on these findings, we expected 
the pathologic Thr175Asp construct to form fibrils when the PAD was unmodified (Thr175Asp-
Tyr18WT) or unphosphorylated (Thr175Asp-Tyr18Phe) but reduced when pseudophosphorylated 
(Thr175Asp-Tyr18Glu). However, we demonstrated that both mutation of the PAD to Tyr18Phe and 
Tyr18Glu resulted in impaired PAD-PP1 binding and reductions in fibril formation, representing a 
discrepancy between our findings those found by Kanaan and colleagues (2012).  
The discrepancy between our findings is specific to the Tyr18Phe mutation, which Kanaan 
and colleagues’ data suggests does not interfere with PAD-PP1 binding. Our the data in the current 
thesis indicates that it does and to a similar degree as with Tyr18Glu pseudophosphorylated 
mutants. The expression of our constructs in vivo as monomeric tau proteins allows for critical 
post-translational modifications to occur, which would not occur to the same degree when 
introducing insoluble tau fibrils to an ex vivo system. Although there are no post-translation 
modifications to Phe that are not shared with Tyr, it is possible that the mutation of Tyr18 might 
influence additional post-translational modifications that occur on neighbouring residues within or 
near the PAD which contribute to impaired PAD-PP1 binding. Group-based prediction software 
(GPS 2.0; (Xue et al., 2008) utilizes machine learning algorithms to make predictions regarding 
post-translational modifications to proteins based on motifs within the primary sequence of a 
protein, considering 7 aa both up- and down-stream of a target residue. Interestingly, an analysis 
of protein post-translational modifications comparing our three PAD mutant constructs 
(Thr175Asp-Tyr¹⁸WT, Thr175Asp-Tyr¹⁸Phe, Thr175Asp-Tyr¹⁸Glu) using bioinformatic group-based 
prediction software identified a difference in the acetylation of Lys24 of tau between these 
constructs. Specifically, the prediction score indicating the probability of acetylation of this residue 
was elevated for both Tyr18Phe and Tyr18Glu constructs relative to that of wild type. Therefore, 
when utilizing site-directed mutagenesis to mimic phosphorylation at a specific residue, it is 
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important to recognize the complex interplay between diverse post-translational modifications to 
a protein of interest which might also be affected. 
Determining the precise mechanisms by which mutation of Tyr18 to either Phe or Glu result 
in a reduction of PAD-PP1 binding requires further experimental study. Nonetheless, it is known 
that phosphorylation of Tyr18 impairs the PAD-PP1 interaction, which this thesis has supported is 
critical in tau fibril formation in vitro following the phosphorylation of tau at Thr175.   
5.1.7 Potential explanations for the lack of increases in active GSK3β expression 
following TBI in vivo 
Our previous experiments have shown an increase in active GSK3β (pTyr216 GSK3/Total GSK3β) 
90 days following an equivalent injury in adult female Sprague Dawley rats (Moszczynski et al., 
2018b). Despite the current experiment utilizing an equivalent injury in rodents of the same sex, 
age, and strain, no changes in pTyr216 GSK3β levels were found following TBI. One potential 
explanation for the discrepancy between our findings include differences in the lysis procedure 
utilized. Our previous investigations homogenized whole left or right hemispheres, followed by a 
brief centrifugation at 10,000 RPM to clear DNA and lipid membrane. However, the current series 
of experiments utilized a much more rigorous lysis and clearing procedure, which was required in 
order for us to send samples to Kinexus Proteomics for phosphosite profiling analysis. Specifically, 
the clearing procedure involved a 30-minute ultracentrifugation at 90,000g, which might have 
pelleted aggregated proteins and large multiprotein complexes that were not effectively 
homogenized, thus removing those proteins from the Western blot analysis. In support of this 
postulate, we have observed previously that pTyr216 GSK3β is present within pThr175 and pThr231 
tau immunoreactive aggregates in vivo (Moszczynski et al., 2018a). Thus, if these aggregates were 
not effectively homogenized, they might have pelleted the phosphorylated GSK3β epitope of 
interest, resulting in the discrepancy between our findings.  
5.1.8 Implications for pThr175 tau on Thr231 phosphorylation 
Although Experimental Set 1 demonstrated the mechanism of toxicity of Thr175Asp tau to be 
dependant upon interactions between the tau PAD and PP1, there may be other mechanisms at 
play which contribute to the propagation of this tauopathy and the formation of fibrils. Intriguingly, 
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it was noted that the fibrils formed by Thr175Asp tau were qualitatively different than those of 
Thr175WT and Thr175Ala fibrils, possessing denser curvilinear fibrils in vitro. (Figure 3.7B). 
Indeed, PAD mutation of Tyr18 resulted in a decrease in the percentage of cells containing fibrils, 
but those that possessed fibrils were still distinct from those of Thr175WT and Thr175Ala tau, 
indicating that pseudophosphorylation at Thr175 may have additional structural effects on fibril 
formation.  
Fibril formation in this model has been shown to be dependant upon the additional 
phosphorylation of tau at Thr231 (Moszczynski et al., 2015), and it is possible that our Thr175Asp 
mutant affects this phosphorylation event as well. Intriguingly, recent investigations have 
identified the cis-pThr231 conformer as pathologic, whereas the trans-pThr231 conformer regulates 
microtubule stabilization under physiological conditions (Albayram et al., 2017). The peptidyl-
prolyl isomerase 1 (Pin1) enzyme catalyzes the conversion of cis-pThr231 to the physiologic trans 
conformation (Lu, Wulf, Zhou, Davies, & Lu, 1999; Ma, Pastorino, Zhou, & Lu, 2012). It is also 
possible that phosphorylation of tau at the Thr175 residue modifies the propensity of Thr231 to be 
phosphorylated by GSK3β in the cis conformation, thereby increasing the abundance of the cis-
pThr231 conformer and contributing to denser pathologic fibril formation. Alternatively, the 
Thr175Asp mutation might impair the ability for Pin1 to bind to cis-pThr231 tau and catalyze the 
isomerization to the trans physiologic form, thereby contributing to the accumulation of this 
pathologic epitope and resultant fibril formation. These specific hypotheses were not able to be 
tested in the current thesis due to lack of availability of cis and trans specific pThr231 antibody.  
5.2 Limitations of Study 
5.2.1 External validity of eGFP-tagged tau protein constructs 
The first limitation of the in vitro experiments involved the tau protein constructs utilized. To be 
consistent with previous experiments conducted in our lab, eGFP-tagged tau protein constructs 
were used for all assays. It is important to note that the eGFP tag is added onto the N-terminus of 
the tau protein construct, immediately adjacent to the PAD. Therefore, investigations concerning 
PAD exposure in this model are complicated by this addition, as all tau protein constructs utilized 
may have a slightly different conformation with and without the tag. Conformational changes to 
tau protein due to the addition of an N-terminal eGFP tag might explain why all three Thr175 tau 
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protein constructs assessed (Thr175WT, Thr175Ala, and Thr175Asp) possessed some PAD exposure 
when assessed by dot blotting. Notwithstanding this, our Thr175Asp mutant possessed a significant 
elevation in PAD exposure, which was large enough to initiate tau protein fibril formation via a 
PAD-mediated mechanism. The dynamic tertiary structure of tau protein might allow for transient 
PAD exposure to occur under physiological conditions, with only persistent PAD exposure (in 
large quantities) being pathologic. In this way, Thr175WT and Thr175Ala mutants might have 
possessed some transient PAD exposure in our model, whereas Thr175Asp tau protein is held open 
by pseudophosphorylation at the critical Thr175 residue. Despite these limitations, the fact that 
modifications of tau protein at Thr175 has impactful downstream structural consequences on the 
tau N-terminus is robustly supported in the current thesis. The in vitro evidence directly showing 
this relationship is further supplemented with results from our TBI-induced tauopathy model, 
which demonstrate that pThr175 tau formation highly colocalizes with PAD exposure in vivo. 
5.2.2 Tau protein isoforms utilized 
The current set of in vitro experiments utilized eGFP-tau protein constructs of the longest isoform 
(2N4R). Previous investigations concerning the pathogenicity of our Thr175Asp mutant construct 
utilized all six tau protein isoforms, and found that the results between constructs did not 
significantly differ; the net result was that pseudophosphorylation at Thr175 was associated with 
pathologic fibril formation, regardless of the isoform utilized (Gohar et al., 2009). Subsequent 
investigations concerning the activation of GSK3β in this model focused solely on the longest tau 
protein isoform (Moszczynski et al., 2015). As the current series of in vitro experiments act as an 
extension of that research, we limited our investigation to the study of 2N4R tau fibril formation. 
However, it is worth noting that the tau PAD lies adjacent to the two N-terminal repeat regions, 
meaning that PAD-mediated neurotoxicity might be influenced by the number of N-terminal 
repeats present in tau protein. Additionally, since tau protein’s hairpin conformation relies on 
interactions with the tau C-terminus, shorter 3R tau protein isoforms might not hide the PAD from 
interaction with PP1 to the same degree of 4R tau protein isoforms. The determination of what 
role these N-terminal repeats and microtubule-binding domains play in PAD exposure and 
subsequent fibril formation would need to be determined in future study.  
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5.2.3 The use of animal models for the study of tauopathy 
Our in vivo TBI experiments utilized wild-type adult female Sprague Dawley rats. There are 
numerous important differences between human tau protein and that of rodents such as rats and 
mice that may complicate the results of experiments utilizing these animals as model systems. Two 
main considerations in the use of rodents as animal models in the study of tauopathy include 
differences in tau primary sequence, and isoform expression.  
In considering only the longest tau protein isoform, the primary sequences of human and 
rat tau protein share approximately 74.68% homology. Similarly, mouse tau shares 74.19% 
homology with humans, but only 91% homology with rats, indicating that although rats and mice 
possess very similar tau protein primary structure, there are differences in amino acid sequence 
between these animals. Importantly, there are differences in tau protein primary sequence within 
regions critical to the current thesis (Figure 5.2). The tau protein PAD appears to be largely 
conserved between these two organisms with 14 of the 18 residues within the PAD being the same. 
However, of the residues which are not shared between these organisms, there are a number of 
critical differences in the sidechains of modified amino acids. In examining the primary sequence 
within the PAD, the Glu9Asp (format ‘HumannRat’) modification conserves the presence of two 
charged amino acids and might not have as much of a structural impact as the Val10Thr 
modification which switches a hydrophobic Val residue for a polar Thr residue. However, the 
specific functional consequences of these modifications on the critical PAD-PP1 interaction cannot 
be predicted without explicit experimentation. Importantly, both of these organisms contain a Tyr18 
residue, a Fyn kinase targeted amino acid who’s phosphorylation is important for the reduction of 
PAD-mediated neurotoxicity (Kanaan et al., 2012).  
The Thr175 residue in both rat and human tau protein is preceded by the ‘PAK’ motif. 
However, Thr175 in humans is followed by 2 Pro residues, which may be important for the binding 
of Pro-directed kinases within the MAPK family, many of which are tau protein kinases. In rats, 
the Thr175 residue is followed by another Thr and then a Pro residue, thereby potentially 
contributing to differences in the kinases this epitope interacts with. That being said, both rats and 
human express tau protein with a Thr175 flanked by a Pro residue, and pThr175 in both rats and 
humans has been strongly associated with the development of tauopathy.  
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Human tau protein 3R and 4R isoforms are expressed in an approximate ratio of 1:1 in 
healthy adults. However, in certain neurodegenerative diseases for which tau protein inclusion 
formation is a feature, this ration is found to be disturbed. For example, a large analysis of 
individuals with frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17; 
formerly ‘Pick’s disease) have been shown to possess a triplet of missense mutations at the 5’ end 
of exon 10, resulting in decreased splicing at this site an a large decrease in the 3R:4R tau ration 
(Hutton et al., 1998). The relative abundance of 4R isoform expression is also a feature of 
Alzheimer’s disease and is absent in age-matched controls (Ginsberg, Che, Counts, & Mufson, 
2006). Therefore, the relative amounts of both 3R and 4R tau protein expressed in an organism is 
a relevant variable to consider when examining the external validity of an animal model. Although 
rats and mice are phylogenetically very similar, sharing the Rodentia genus, the expression of tau 
protein isoforms is found to differ between these organisms. Importantly, rats express all six tau 
protein isoforms shared with humans (Hanes et al., 2009) whereas mice only express 4R tau protein 
(Liu & Götz, 2013). Given the demonstrated importance of 3R:4R expression in humans, the use 
of an animal model which expressed all six tau protein isoforms was a consideration when deciding 
whether to use rats or mice in our in vivo experiments.   
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Figure 5.2 Primary sequence comparison of tau protein present in Rattus norvegicus and Homo 
sapiens containing all exons. Bolded sequence in blue denotes residues present within the tau PAD. 
The Thr175 residue is represented as the bolded red character.  
Human  1    MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG  60 
            MAEPRQEF+ MED AG Y           TM QDQEGD D GLKESP Q P +DGSEEPG 
Rat    1    MAEPRQEFDTMEDQAGDY-----------TMLQDQEGDMDHGLKESPPQPPADDGSEEPG  49 
 
Human  61   SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG  120 
            SETSDAKSTPTAEDVTAPLV+E AP KQA AQ HTEIPEGTTAEEAGIGDTP++ED+AAG 
Rat    50   SETSDAKSTPTAEDVTAPLVEERAPDKQATAQSHTEIPEGTTAEEAGIGDTPNMEDQAAG  109 
 
Human  121  HVTQEPESGKVVQEGFLREPG-------PPGLS---HQLMSGMPGAPLLPEGPREATRQP  170 
            HVTQEP+  ++  +  L EPG         G+S   HQ +  M GAPL P+G REAT QP 
Rat    110  HVTQEPQKVEIFSQSLLVEPGRREGQAPDSGISDWTHQQVPSMSGAPLPPQGLREATHQP  169 
 
Human  171  SGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQ  230 
             GT PED E    A ELL  +          P K A GK+R GS+EEVDED  +DESS Q 
Rat    170  LGTRPEDVERSHPASELLWQES---------PQKEAWGKDRLGSEEEVDEDITMDESS-Q  219 
 
Human  231  DSPPSKASPAQDGRPPQT-------AAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASE  283 
            +SPPS+AS A     PQ         + E TSIPGFPAEG+IPLP DF SKVS E  AS  
Rat    220  ESPPSQASLAPGTATPQARSVSASGVSGETTSIPGFPAEGSIPLPADFFSKVSAETQASP  279 
 
Human  284  PDGPSVG-RAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSL  342 
            P+GP  G   +G +A  EFTFHVEI  +  KEQ      L  A   GAP E  +ARGPS+ 
Rat    280  PEGPGTGPSEEGHEAAPEFTFHVEIKASAPKEQ-----DLEGATVVGAPAEEQKARGPSV  334 
 
Human  343  GEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAK  402 
            G+ TKEA L EP++KQPAA   G+PVSRVPQLKAR+   SKD TG+D+KKAKTST S AK 
Rat    335  GKGTKEASLLEPTDKQPAAGLPGRPVSRVPQLKARVAGVSKDRTGNDEKKAKTSTPSCAK  394 
 
Human  403  TLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGA  462 
            T  NRPCLSP  PTPGSSDPLI+PSSPAVCPEP +SPKYVSSVT R GS G K+MKLKGA 
Rat    395  TPSNRPCLSPTRPTPGSSDPLIKPSSPAVCPEPATSPKYVSSVTPRNGSPGTKQMKLKGA  454 
 
Human  463  DGKT--KIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSP  520 
            DGKT  KIATPRGAA PGQKG +NATRIPAKT P+PKTPP SGEPPKSG+RSGYSSPGSP 
Rat    455  DGKTGAKIATPRGAATPGQKGTSNATRIPAKTTPSPKTPPGSGEPPKSGERSGYSSPGSP  514 
 
Human  521  GTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGST  580 
            GTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPS++KSRLQTAPVPMPDLKNV+SKIGST 
Rat    515  GTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSASKSRLQTAPVPMPDLKNVRSKIGST  574 
 
Human  581  ENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCG  640 
            ENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSV IVYKPVDLSKVTSKCG 
Rat    575  ENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVHIVYKPVDLSKVTSKCG  634 
 
Human  641  SLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAK  700 
            SLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAK 
Rat    635  SLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAK  694 
 
Human  701  AKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL  758 
            AKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL 
Rat    695  AKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL  752 
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5.2.4 Limitations in the assessment of phosphorylation status of GSK3β 
We had hypothesized that the mechanistic connection between tau PAD exposure and fibril 
formation is accomplished via a PP1-mediated reduction in pSer9 GSK3β. However, although 
modifications to GSK3β at Ser9 site serve a critical regulatory role on GSK3β activity, it is well-
documented that the abundance of this epitope is low in physiological conditions. Because of this, 
immunodetection of pSer9 GSK3β by Western blotting was not successful for all experiments. 
Moreover, the assessment of pSer9 GSK3β and pTyr216 GSK3β are indirect and imperfect 
measurements of GSK3β activity. The assessment of GSK3β activity has been measured via 
changes in phosphorylated β-catenin in the cell, with increased phosphorylation indicative of 
greater GSK3β activity (Noort, Meeldijk, Zee, Destree, & Clevers, 2002; Yeow et al., 2006). 
Therefore, the assessment of β-catenin phosphorylation might have served as a better indicator of 
GSK3β activity in Experimental Set 1. However, in this case we used fibril formation as a 
functional assay of GSK3β activity, since it has been previously shown that it is increases in 
GSK3β activity which result in Thr175Asp fibril formation (Moszczynski et al., 2015).  
5.3 Future Directions 
5.3.1 Future immunohistochemical investigations 
The large amount of tissue generated in Experimental Set 2 was utilized in the current thesis to 
examine the colocalization of pThr175 tau and exposed PAD throughout the development of pThr175 
tau fibrils following TBI. However, the generation of this large amount of tissue will allow for the 
subsequent investigation of a plethora of diverse pathological processes in response to TBI in our 
model. Included in this analysis is the potential of temporal spreading of tau pathology from the 
ipsilateral to contralateral hemisphere relative to the injury, as our previous studies have shown 
trends of increasing pThr175 tau contralateral to an injury by 90 days following TBI. In 
characterizing the spreading of pThr175 tau pathology over time, we can better understand the 
processes by which tau protein pathology might propagate between and affect multiple brain 
regions in an individual who has experienced a TBI. The study of potential pathologic tau 
spreading in response to TBI is the subject of current investigations in our lab. Additionally, recent 
focus has been placed on the diverse set of proteinopathies that may act together to contribute to 
neurodegeneration. Indeed, some evidence has suggested the importance of dual mechanisms of 
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neurotoxicity involving multiple proteinopathies. The identification of multiple pathologies is 
common when examining the brains of individuals with neurodegenerative conditions. For 
example, the neuropathological examinations of some individuals with Alzheimer’s disease have 
reported the presence of TDP-43 (Amador-Ortiz et al., 2007; Josephs, Murray, et al., 2014; 
Josephs, Whitwell, et al., 2014). Similarly, our recent investigations has demonstrated the presence 
of pThr175 tau protein in many neurodegenerative diseases associated with other ‘-opathies’, 
including synuclein and Amyloid  (Moszczynski et al., 2017). The large amount of tissue collected 
in Experimental Set 2 will be utilized in future investigations to examine the complex interplay 
between the numerous neurodegenerative conditions of which TBI is a risk factor, including but 
not limited to: CTE, ALSci, and Alzheimer’s disease (McKee et al., 2009; Moszczynski, 
Hintermayer, et al., 2018; Moszczynski et al., 2017; Moszczynski et al., 2016; Ramos-Cejudo et 
al., 2018).  
5.3.2 Kinase modification may inform pharmacotherapeutic interventions for 
TBI  
The large amount of data that was obtained by our mass phospho-site Kinexus profiling has 
identified numerous kinases which are responsive to TBI, and which might contribute to the 
development of tau pathology, and perhaps other proteinopathies as well. One fundamental 
conclusion from the current thesis is that the pathologic phosphorylation of tau at Thr175 is an early 
event in tau pathogenesis and contributes to the development of fibrils. Therefore, the 
identification of the kinase that is responsible for this initial pathologic phosphorylation event 
would inform pharmacotherapies for acute intervention following TBI, as reducing or eliminating 
pThr175 tau formation might reduce or eliminate the formation of cytotoxic tau fibrils in vivo.  
Although not explicitly examined in the current thesis, results from our mass kinase screen 
suggest that c-Jun N-terminal kinase (JNK), GSK3β, p38, ERK1 or AKT1 might be responsible 
for this early pathologic phosphorylation of tau protein, being activated between 0-24 hours 
following TBI in our model (Figure 4.7). An experiment examining various tau kinases in vitro 
demonstrated that human tau protein can be phosphorylated at the Thr175 residue by all of JNK, 
GSK3β, p38, and ERK2, further supporting the role of these kinases in this aberrant 
phosphorylation event in vivo (Hanger et al., 1998). Furthermore, a group-based prediction 
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software (GPS 2.0; Xue et al., 2008) algorithm was utilized to examine the probability of 
phosphorylation at Thr175 by 408 protein kinases present in the human proteome. This algorithm 
examined the primary sequence of the substrate and considered 14 residues surrounding the residue 
of interest to predict probable kinase-substrate relationships. This analysis yielded the highest 
prediction for JNK2 to phosphorylate tau protein at Thr175, suggesting that this kinase as well as 
ERK1/2, FRAP, and CDK1/5 might phosphorylate tau protein at Thr175 (Figure 5.2). Given that 
JNK and ERK (known tau kinases) are predicted to preferentially phosphorylate tau protein at this 
site and are upregulated in vivo at early timepoints following TBI correlating well with pThr175 
formation, it is reasonable to examine the effect of pharmacological inhibition of these kinases on 
pThr175 tau pathogenesis. The role of these kinases in the formation of pThr175 tau in vitro is the 
subject of current investigations in our lab.  
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Figure 5.2 Kinase prediction for the phosphorylation of human tau protein at Thr175. 
Bioinformation Group Position Software 2.0 (Xue et al., 2008) was utilized to compute a 
prediction score for the kinase(s) that most probably phosphorylate tau protein at Thr175. Analysis 
was conducted based on motifs present on the 14 residues (7 upstream, 7 downstream) that 
surround Thr175. Greatest prediction scores were for JNK2, ERK1/2, FRAP, and CDK1/5.  
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Conclusion 
The phosphorylation of tau protein at Thr175 is a pathologic event, associated with the formation 
of tau protein fibrils in a GSK3β-dependant manner both in vitro and in vivo. The current thesis 
sought to examine the mechanisms of Thr175-mediated GSK3β activation and its role in tau 
pathogenesis and has utilized both in vitro and in vivo methods to do so. Experimental Set 1 
demonstrated that pseudophosphorylated Thr175Asp tau pathologic fibril formation is dependant 
on GSK3β activation and PAD exposure. Mutation of the PAD in vitro impaired tau’s interaction 
with PP1 and resulted in a reduction of pathologic fibril formation. Experimental Set 2 
demonstrated that pThr175 tau and exposed PAD co-occur in vivo in response to rodent TBI and 
are associated throughout the development of tau protein pathology. These data collectively 
suggest a positive feedback model of tau protein pathogenesis by which the aberrant 
phosphorylation of tau at Thr175 initiates a pathologic process involving increases in tau PAD 
exposure, resulting in increases in tau-PP1 binding, and GSK3β activity, and the 
hyperphosphorylation of tau protein resulting in fibril formation. Although we were not able to 
directly demonstrate this mechanism of tau pathogenesis in vivo, future experiments 
pharmacologically targeting GSK3β or the abnormal PAD-PP1 complex formed following rodent 
TBI will confirm the degree of translation between our in vitro and in vivo models. This research 
will serve broad implications concerning the pharmacological targets for therapeutic intervention 
in the treatment of tauopathy in humans.  
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Approximately 50–60% of all patients with amyotrophic lateral sclerosis (ALS) will develop
a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to
one or more deficits of neuropsychological, speech or language function which are
collectively known as the frontotemporal spectrum disorders of ALS (ALS-FTSD). While
the neuropathology underlying these disorders is most consistent with a widespread
alteration in the metabolism of transactive response DNA-binding protein 43 (TDP-43),
in both ALS with cognitive impairment (ALSci) and ALS with FTD (ALS-FTD; also known
as MND-FTD) there is evidence for alterations in the metabolism of the microtubule
associated protein tau. This alteration in tau metabolism is characterized by pathological
phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with
activation of GSK3β (pTyr216GSK3β), phosphorylation of Thr231tau, and the formation
of cytoplasmic inclusions with increased rates of cell death. This putative pathway
of pThr175 induction of pThr231 and the formation of pathogenic tau inclusions has
been recently shown to span a broad range of tauopathies, including chronic traumatic
encephalopathy (CTE) and CTE in association with ALS (CTE-ALS). This pathway can be
experimentally triggered through a moderate traumatic brain injury, suggesting that it is
a primary neuropathological event and not secondary to a more widespread neuronal
dysfunction. In this review, we discuss the neuropathological underpinnings of the
postulate that ALS is associated with a tauopathy which manifests as a FTSD, and
examine possible mechanisms by which phosphorylation at Thr175tau is induced. We
hypothesize that this might lead to an unfolding of the hairpin structure of tau, activation
of GSK3β and pathological tau fibril formation through the induction of cis-Thr231
tau conformers. A potential role of TDP-43 acting synergistically with pathological tau
metabolism is proposed.
Keywords: amyotrophic lateral sclerosis, chronic traumatic encephalopathy, frontotemporal dementia, TDP-43,
microtubule associated tau protein
Moszczynski et al. Alterations in Tau Metabolism in ALS
INTRODUCTION
Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease) has
classically been considered to be a disorder purely of the
descending supraspinal and lower motor neurons, the net result
of which is an insidiously progressive degenerative process
culminating in death within 3–5 years following symptom onset
for the majority of patients (Charcot and Joffroy, 1869; Strong,
2003). However, the concept that ALS is a pure motor disorder
has been gradually replaced by one in which it is recognized that
between 50 and 60% of all ALS patients will have a concurrent
disorder of frontotemporal function (Strong, 2008; Elamin et al.,
2011; Phukan et al., 2012; Oh et al., 2014; Montuschi et al.,
2015; Strong et al., 2017). Although the literature historically
contained a number of individual ALS case reports in whom
a concurrent neuropsychological or behavioral disorder had
been identified, the recognition that a significant proportion of
ALS patients could also have a frank dementia is more recent
(Hudson, 1981; Bak and Hodges, 2001). It is now recognized
that ALS can include a broad range of neuropsychological,
speech, language, or behavioral pathologies that have recently
been termed “amyotrophic lateral sclerosis – frontotemporal
spectrum disorder (ALS-FTSD)” (Strong et al., 2017). ALS-
FTSD includes impairments in cognition (ALSci), behavioral
dysfunction (ALSbi), a dysexecutive syndrome (ALScbi), or
a frontotemporal dementia (ALS-FTD) meeting the Neary or
Hodges criteria (Neary et al., 1998; Hodges and Miller, 2001;
Rascovsky et al., 2007).
As our understanding of the clinical phenomenology
of ALS-FTSD has evolved, so too has our understanding
of its pathobiology. In contemporary nomenclature, the
frontotemporal lobar degenerations (FTLD) are categorized
into three neuropathological subtypes depending on the pattern
of pathological protein deposition that is observed: FTLD-
tau for those in which a tauopathy [pathological inclusions
consisting of the microtubule associated protein tau (tau)]
is clearly evident; FTLD-TDP for those in which transactive
response DNA-binding protein of 43 kDa (TDP-43) deposition
as neuronal or glial inclusions is the hallmark; and, FTLD-FUS
for a small proportion of cases in which the DNA/RNA binding
protein, fused in sarcoma (FUS), is deposited. For a minority of
cases, none of these markers are evident, but there is evidence
of widespread protein ubiquitin conjugation, suggesting a
disorder of the ubiquitin-proteasome system (UPS). In this latter
subgroup, the terminology FTLD-UPS is applied. Finally, an
exceptionally rare subgroup will demonstrate a FTLD in which
the molecular pathology (i.e., tau, TDP-43, FUS or ubiquitin) is
not known, in which case the terminology of FTLD-NOS (not
otherwise specified) is applied (Mackenzie et al., 2011; Irwin
et al., 2015).
In its most florid form, ALS-FTSD bears all of the
neuropathological features of a FTLD in which there is a strong
positive correlation between the degree of cognitive dysfunction
and the extent of pathological intraneuronal deposition of TDP-
43 (Cykowski et al., 2017). Typically observed as a predominantly
nuclear protein, in ALS and under conditions of neuronal
stress or injury, TDP-43 undergoes a marked upregulation in
its expression and adopts a predominantly cytosolic localization
(Arai et al., 2006; Neumann et al., 2006; Mackenzie et al., 2011).
This applies to both motor neurons and cortical neurons where
the latter forms the basis for characterizing the FTLD of ALS
as FTLD-TDP. This has been taken therefore to imply that
the frontotemporal dysfunction of ALS cannot be grounded in
alterations in the metabolism of tau, or potentially as an overlap
syndrome. In this review, we will examine the evidence for
alterations in tau metabolism in ALSci, and provide the basis for
the consideration of this disorder as a tauopathy that is tightly
integrated with the dysmetabolism of TDP-43.
ALS-FTSD: CLINICAL & NEUROIMAGING
CHARACTERIZATION
The presence of frontotemporal dysfunction in an ALS patient is
a negative prognostic indicator, heralding a significant reduction
in survivorship. This is particularly true for those individuals
in which the primary manifestation is either a dysexecutive
syndrome or behavioral impairment (Olney et al., 2005; Elamin
et al., 2011; Hu et al., 2013). While current epidemiological
studies consider a range of prognostic factors that can have an
impact on survivorship such as age of onset, rate of deterioration
as measured by the ALSFRS–R Total Score, diagnostic delay,
age at diagnosis, and metabolic markers, it is noteworthy that
few account for the presence or absence of neuropsychological,
speech or language dysfunction as a significant prognostic
variable (Chiò et al., 2009; Lunetta et al., 2015; Couratier et al.,
2016). In part, this may represent a bias introduced because of the
complexity of detecting neuropsychological, speech, language, or
behavioral impairments (Farhan et al., 2017). Because of this,
the Strong criteria (2009) have been recently revised to increase
the simplicity and applicability of these international consensus
criteria (Strong et al., 2009, 2017).
Revision of the Strong criteria was also driven by the need
to broaden the definition of frontotemporal spectrum disorder
in ALS to include deficits in social cognition, including deficits
in Theory of Mind (ToM). ToM refers specifically to the
capacity to attribute independent mental states to others, and
can be divided into an affective and cognitive component. The
affective component of ToM refers to one’s ability to make
inferences regarding the emotions and feelings of others, whereas
the cognitive component refers to the ability to infer others’
intentions and beliefs (Shamay-Tsoory et al., 2009; Adenzato
et al., 2010; Poletti et al., 2012). Deficits in both social cognition
and ToM, localizing to the mesial frontal/anterior cingulate, are
present in a significant proportion of ALS patients, even when
there is no clear evidence to suggest more widespread higher-
order cortical dysfunction (Meier et al., 2010; Girardi et al., 2011;
Poletti et al., 2012; Cerami et al., 2014; van der Hulst et al., 2015).
This suggests that deficits in social cognition and ToM might be
the earliest harbinger of frontotemporal dysfunction in ALS.
The concept of non-motor dysfunction in ALS being reflective
of a widespread higher cortical impairment—with a degree of
preponderance to the frontal lobes, particularly the mesial frontal
cortex—is supported by a broad array of neuroimaging studies
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(Abrahams et al., 2004; Lillo et al., 2010; Agosta et al., 2011,
2013; Goldstein et al., 2011; Prudlo et al., 2012; Ambikairajah
et al., 2014). Such studies need to be interpreted in the light of
underlying genetic traits of the individuals being studied, as it
is increasingly clear that ALS is also syndromic with the clinical
and molecular phenotype being driven by an ever-increasing
array of known genetic variants (Strong, 2001, 2017; Turner
and Verstraete, 2015). The contributions of neuroimaging have
extended beyond identifying the general degree of cerebral
atrophy accompanying frontotemporal syndromes, as visualized
with either computed tomography (CT) or magnetic resonance
imaging (MRI). Neuroimaging platforms such as single positron
emission computerized tomography (SPECT) (Neary et al.,
1990), MRI-based measures of functional connectivity (Douaud
et al., 2011), and advanced structural MRI sequences that
define subcortical frontotemporal white matter tract projection
pathology (Agosta et al., 2016) can now provide an evaluation
of the extent of loss of functional integrity. Positron emission
tomography (PET) has proven invaluable in our understanding
of the anatomic and cellular extent of the pathobiology of ALS-
FTSD, including the involvement of non-neuronal cells in the
disease process (Cistaro et al., 2012, 2014). Increasingly, these
neuroimaging modalities are being linked to understanding the
molecular pathology of ALS, such as the degree of deeper cortical
structures and cerebellar pathology evident in those ALS patients
carrying pathological hexanucleotide expansions in C9orf72,
even in the presymptomatic stages (Mahoney et al., 2012; Bede
et al., 2013; Rohrer et al., 2015; Walhout et al., 2015).
Our interest in the pathology of the anterior cingulate gyrus in
ALS, and ultimately the importance of alterations in metabolism
of the microtubule-associated protein tau, was driven by a broad
array of evidence suggesting that alterations in verbal praxis and
fluency were key harbingers of higher cortical dysfunction in
the disease (Strong et al., 1996). In a prospective study designed
to assess the degree of neuronal loss in the anterior cingulate
gyrus using 1H-magnetic resonance spectroscopy (1H-MRS), we
observed a significant reduction in the NAA/Cr ratio (indicative
of neuronal loss) at baseline. This corresponded to early features
of cognitive impairment at a time when no changes in the
NAA/Cr ratio were observed in the motor cortex in the region
of hand representation (Strong et al., 1999). In hindsight, when
we returned to these studies to correlate the placement of the
STEAM (Stimulated Echo Acquisition Mode) voxel for mesial
frontal localization, the localization was predominantly area 24,
showing that the region of neuronal loss correlated with those
regions described earlier as encoding social cognition and ToM.
As will be reviewed below, it was the neuropathological study of
these cases that has driven our conceptualization of a tauopathy
in association with ALS-FTSD.
ALS-FTSD: NEUROPATHOLOGICAL
CHARACTERIZATION
Alterations in RNA Metabolism
Pathological intracellular protein inclusions are amongst the
neuropathological hallmarks of ALS and include proteins such
as copper/zinc superoxide dismutase 1 (SOD1) (Chou et al.,
1996), TDP-43 (Arai et al., 2006; Neumann et al., 2006), fused in
sarcoma/translocated in liposarcoma (FUS/TLS) (Kwiatkowski
et al., 2009; Vance et al., 2009), TATA-binding protein-associated
factor 15 (TAF-15) (Couthouis et al., 2011), Ewing sarcoma
breakpoint region 1 (EWSR1) (Couthouis et al., 2011), RNA-
binding motif 45 (RBM45) (Collins et al., 2012), Rho guanine
nucleotide exchange factor (RGNEF) (Volkening et al., 2010;
Keller et al., 2012), intermediate filament proteins (neurofilament
Strong et al., 2005 or peripherin Migheli et al., 1993), 14-3-3
proteins (Malaspina et al., 2000; Kawamoto et al., 2004), and
abnormal dipeptide repeat (DPR) proteins arising from C9orf72
G4C2 repeat expansions through repeat associated non-AUG
(RAN) translation (Ash et al., 2013; Mori et al., 2013).
Amongst these proteins, it is the presence of TDP-43
immunoreactive neuronal cytoplasmic inclusions (NCIs) within
degenerating motor neurons that is now recognized as being a
ubiquitous neuropathological feature of all variants of ALS, with
the exception of cases in which mutations in SOD1 are present.
TDP-43 is a dual DNA/RNA binding protein whose metabolism
is fundamentally altered in ALS and which forms the core protein
of the vast majority of neuronal and glial inclusions in ALS,
FTD, and ALS-FTSD (Arai et al., 2006; Neumann et al., 2006).
Typically, TDP-43 is predominantly nuclear in its localization,
but in response to cellular injury, its expression is markedly
upregulated in a process that is accompanied by a nuclear to
cytosolic shift in its localization (Moisse et al., 2009a,b). There is
a high degree of correlation between the severity of the cognitive
deficit that occurs in ALS and the distribution and extent of
pathological TDP-43 deposition (Mackenzie, 2008; Mackenzie
et al., 2011; Cykowski et al., 2017). Because of this prominence
of TDP-43 pathology, and a general lack of deposition of the
microtubule associated tau protein, the FTLD of ALS-FTD is
currently classified as a “TDP-43 proteinopathy” and not a “tau
proteinopathy.”
pThr175 Tau and Alterations in Tau
Metabolism
Notwithstanding this, the evidence in support of alterations
in tau metabolism in ALS is robust, including that observed
in the hyperendemic focus of ALS in the western Pacific in
which the deposition of tau protein is prominent throughout the
neuroaxis (Hirano, 1966). The presence of tau pathology has also
been described in both sporadic and familial ALS case reports
(Orrell et al., 1995; Soma et al., 2012; Dobson-Stone et al., 2013;
Nakamura et al., 2014; Takeuchi et al., 2016). Additionally, several
more recent studies have reported an elevation in phosphorylated
and truncated tau protein in both hippocampal and spinal cord
neurons of various ALS populations (Gómez-Pinedo et al., 2016;
Vintilescu et al., 2016).
Our interest in the pathological processing of tau protein
in ALS was initially aimed at explaining the basis of the
superficial linear spongiosus evident in the anterior cingulate
gyri of those ALSci patients in whom we observed a loss of
neurons in this region through 1H-MRS (Strong et al., 1999;
Wilson et al., 2001). Using antibodies against tau protein as
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a marker of axonal projections which we postulated would be
lost, we instead observed both neuronal and glial cytoplasmic
inclusions which were tau immunoreactive throughout the
affected anterior cingulate gyrus (Yang et al., 2003). This included
a broad range of pathologies, including neurofibrillary tangle-
like structures, dystrophic neurites, neuritic granules, and tau-
immunoreactive tufted astrocytes. We demonstrated that this
was not simply a function of aging as might be expected based
on the subsequently described progressive age-related tauopathy
(Yang et al., 2005; Crary et al., 2014; Jellinger et al., 2015).
Following fractionation of tau protein into sarkosyl-soluble
or insoluble fractions from either the cortical or subcortical
white matter of the anterior cingulate gyrus of ALSci patients,
we observed that in contrast to tau protein isolated from
Alzheimer’s disease in which the insoluble fraction contained
the triplet tau isoforms characteristic of paired helical filaments
(PHFs), all six isoforms of tau protein were expressed in
both the soluble and insoluble fractions (Strong et al., 2006).
We subsequently confirmed this finding independent of the
presence or absence of pathological hexanucleotide expansions
of C9orf 72 (Volkening et al., 2017). In the former study,
we also observed that sarkosyl-insoluble tau protein from
ALSci was resistant to enzymatic dephosphorylation, and, when
examined using the Thioflavin S assay, had a significant increase
in the tendency to form polymers ex vivo (Strong et al.,
2006).
Given this suggestion of pathological tau protein
phosphorylation in ALSci, we conducted a phospho-epitope
analysis and identified a unique tau phosphorylation site at
Threonine 175 (pThr175 tau) in ALS and ALSci that was not
present in either control or AD (both soluble and insoluble tau
protein isolates) (Strong et al., 2006). Using a novel polyclonal
antibody against pThr175 tau, we subsequently confirmed
the presence of prominent tau protein glial and neuronal
cytoplasmic inclusions in ALSci, and to a lesser degree in ALS
without cognitive deficits, in association with an increase in
the expression of active GSK3β (Yang et al., 2008; Yang and
Strong, 2012) (Figure 1). This deposition was accompanied by
a diffuse increase in TDP-43 immunoreactivity, suggesting the
co-occurrence of these pathological processes (Yang and Strong,
2012). The prominent deposition of tau protein, including
pThr175 tau, has been subsequently validated in motor neuron
disease (MND) and MND in the presence of a behavioral
variant of FTD (bvFTD-MND), including the appearance of
tau protein deposition in 10% of MND cases that did not
conform to traditional morphological criteria (unclassified
frontal tau protein) (Behrouzi et al., 2016). While the latter
study suggested a morphological appearance reminiscent of
AD, as discussed earlier, the characteristic sarkosyl-insoluble tau
protein triplet protein molecular signature of AD has not been
observed in ALS or ALSci. More recently, we have observed
that the pathological phospho-epitope pThr175 tau protein is
also observed across a broad range of tauopathies, strongly
suggesting that its presence in ALSci is not simply incidental,
but rather a marker of a fundamental alteration in tau protein
processing across a range of tauopathies (Moszczynski et al.,
2017).
PATHOGENICITY OF pTHr175 TAU
To confirm the pathogenicity of pThr175 tau, we transfected
either HEK293T or Neuro2a cells with a pseudo-phosphorylated
tau protein construct (Thr175Asp-tau), wild type human
tau protein (WT-tau) or human tau protein in which
phosphorylation at Thr175 was irreversibly inhibited (Thr175Ala-
tau) (Gohar et al., 2009). We observed a significant induction of
pathological tau protein cytoplasmic inclusions and enhanced
rates of cell death in the presence of Thr175Asp-tau, regardless of
which of the six human tau protein constructs was transfected.
Consistent with the observed up-regulation of activated
GSK3β (pTyr216GSK3β) that co-localized with tau protein
pathology in ALSci, we demonstrated a significant increase
in pTyr216 GSK3β expression in only the Thr175Asp-tau
transfected cells (Moszczynski et al., 2015). Inhibition of GSK3β
activity, either pharmacologically or by shRNA against GSK3β,
abolished inclusion formation. We next demonstrated that
the development of pathological inclusions in response to the
presence of Thr175Asp-tau was dependent on the unprimed
phosphorylation of the Thr231 residue of tau protein and
that the presence of pThr231 was sufficient to induce tau
protein inclusions. These observations suggest that a pathway
of pThr175 induction of GSK3β activation and a consequent
phosphorylation of Thr231 in tau protein fibril formation is a
pathogenic mechanism contributing to neuronal death in ALSci.
While investigating evidence for this pathway in human disease,
we observed the co-localization of pThr175 and pThr231 in tau
protein NCI-containing hippocampal neurons in ALSci and a
broad range of tauopathies including Alzheimer’s disease, diffuse
Lewy body dementia, and FTLD among others (Moszczynski
et al., 2017). What remains to be determined across both sets
of experiments however is the ultrastructural characteristics of
the cytoplasmic inclusions driven in vitro by pThr175 tau or as
observed in vivo.
We then examined the tauopathy associated with chronic
traumatic encephalopathy (CTE) and CTE with concurrent ALS
(CTE-ALS) (Moszczynski et al., 2018). In both disease states,
the neuropathological hallmark is a disseminated tauopathy
including not only cortical neuronal and glial cytoplasmic
inclusions, but also spinal cord tau protein pathology (McKee
et al., 2009, 2010; Mez et al., 2017). Consistent with a role for
pathological Thr175 tau phosphorylation, we observed pThr175,
pThr231, and T22 immunoreactivity in both hippocampal and
spinal motor neurons. Fractionation of the hippocampal tau
protein into sarkosyl-soluble and insoluble fractions yielded all
six tau protein isoforms partitioning into both fractions, similar
to that observed in ALSci. In support of the hypothesis that
this pathway is directly related to the induction of tau protein
cytoplasmic inclusions, we were able to replicate this pathology
following a single cortical impact (moderate brain traumamodel)
in young adult Sprague Dawley rats (Moszczynski et al., 2018).
While we have suggested that pThr175 tau is critical to
the induction of a tauopathy, this evidence does not prove
it to be sufficient for the development of tauopathy in vivo.
To test this, we utilized the somatic gene transfer of a
pseudophosphorylated human tau protein construct mimicking
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FIGURE 1 | Phosphorylated tau pathology in amyotrophic latera sclerosis with cognitive impairment (ALSci) hippocampal neurons. (A) Immunohistochemical probing
with AT8 (pSer202, pThr205), pThr175, pThr231 all reveal positive inclusions in ALS hippocampal neurons. Images taken with a 100x objective. (B) Representative
image of pThr175 and pThr231 co-localization in ALSci hippocampal neuron. Scale bar = 5µm.
pThr175 tau. Young adult Sprague Dawley rats received
bilateral stereotactic inoculums of a rAAV9 adenoviral construct
containing one of either GFP tagged Thr175Asp-tau (pThr175
tau mimic), GFP-taggedWT-tau, GFP-tagged construct alone, or
GFP-tagged Thr175Ala-tau (Moszcyznski et al., 2017). At 1 year
following inoculation, expression of the viral vector remained
prominent as assessed using anti eGFP immunohistochemistry.
However, the brains of the Thr175Asp-tau inoculated rats
demonstrated prominent neuronal tau protein pathology,
including corkscrew neurites, and tau immunoreactive neuronal
cytoplasmic inclusions.
POSTULATED PATHOGENIC PATHWAY
In support of the pathogenicity of pThr175 tau, phosphorylation
at this site is not observed in fetal human tissue (which is
normally hyperphosphorylated) (Kenessey and Yen, 1993)
or tissue from healthy-aged individuals (Moszczynski et al.,
2017). We have shown in vitro that a pseudophosphorylated
human tau construct (Thr175Asp tau) induces pathological
tau protein inclusions accompanied by the activation
of GSK3β along with phosphorylation of tau at Thr231
(Moszczynski et al., 2015). The in vivo observation of co-
expression of pThr175 tau, pTyr216GSK3β, pThr231 tau, and
immunoreactivity to a tau protein antibody recognizing
oligomeric tau (T22) strongly suggests that this pathway
is critical to the induction of pathological tauopathies,
including ALSci, CTE and CTE-ALS (Moszczynski et al.,
2017, 2018).
The mechanism of Thr175 phosphorylation is not known.
Candidate kinases include mitogen activated protein kinases
(MAPK), GSK3β, p38, and leucine-rich repeat kinase 2
(LRRK2) (Hanger et al., 1998; Reynolds et al., 2000; Atzori
et al., 2001) (see also https://docs.google.com/spreadsheets/d/
1hGYs1ZcupmTnbB7n6qs1r_WVTXHt1O7NBLyKBN7EOUQ/
edit#gid=0). Amongst these, a member of the MAPK
family of kinases, c-Jun N-terminal kinase [JNK; also
known as stress activated protein kinase (SAPK)], is of
specific interest given its increased activity in response
to various cellular stresses in vitro (Namgung and Xia,
2000) and in the acute phases following traumatic brain
injury (TBI) in vivo (Tran et al., 2012). Additionally, the
inhibition of JNK can reduce pathological tau protein
phosphorylation following TBI in a rodent model (Tran
et al., 2012).
Although the mechanism(s) by which the phosphorylation
of tau at Thr175 leads to the activation of GSK3β are not yet
known, it is likely that such mechanism(s) will involve altering
tau’s global hairpin structure given that Thr175 lies within the
Pro-rich domain/hinge region of the hairpin as it has been shown
that the phosphorylation of other residues within this domain
can open the hairpin structure (Jeganathan et al., 2006, 2008).
There are at least two potential mechanisms of GSK3β activation
which may result from tau hairpin structure opening (Figure 2).
Firstly, opening of the hairpin may expose the N-terminus
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FIGURE 2 | Two postulated mechanisms of toxicity following tau protein phosphorylation at Thr175. Opening of the tau hairpin conformation by phosphorylation at
Thr175 exposes SH3 homology domains within the proline-rich region (A). This interacts with and activates FYN kinase, which in turn activates GSK3β by
phosphorylating at Tyr216. Alternatively, opening of the tau hairpin can expose the N-terminal phosphatase activating domain (PAD) (B), which then activates protein
phosphatase 1 (PP1). Activated PP1 dephosphorylates GSK3β at Ser9 increasing its activity. The activation of GSK3β may exert toxic effects in the cell by the
inhibition of fast axonal transport, and by the phosphorylation of tau protein at Thr231, which promotes the formation of neurofibrillary tangles (paired helical filaments;
PHF). Additionally, increased activity of GSK3β can increase the formation of pThr231 tau which also contains an exposed PAD, thereby initiating a dysregulated
positive feedback loop. Activated enzymes are indicated by an asterisk (*).
proline-rich domain, which has been shown to interact with
the SH3 domain of Src-family tyrosine kinase Fyn. In doing
so, activated Fyn kinase may then phosphorylate GSK3β at the
Tyr216 residue thereby enhancing its activity (Lee et al., 1998;
Lesort et al., 1999; Klein et al., 2002). Secondly, opening of the
hairpin conformation has been shown to expose the N-terminal
phosphatase activating domain (PAD), consisting of amino acids
2–18. Exposure of this domain leads to activation of protein
phosphatase-1 (PP1) which then dephosphorylates GSK3β at the
Ser9 residue, enhancing GSK3β activity (Kanaan et al., 2011). In
keeping with this mechanism, exposure of the PAD has been
suggested to be important in tau protein mediated neuronal
toxicity through interference with fast axonal transport, and may
be an early event in the development of a number of tauopathies
(Kanaan et al., 2011, 2016; Ward et al., 2012; Combs et al., 2016).
In the studies cited above, tau phosphorylation at Thr231 is
a critical step in the induction of pathological fibrils. Several
mechanisms have been proposed by which this may occur,
with alterations in tau degradation being key in a process that
is dependent on tau conformation. Of note, cis-pThr231 tau
demonstrates specificity in the development of pathology over
trans-pThr231 tau, in which the cis conformer is pathological and
cannot be degraded, whereas the trans conformer is physiological
and can be degraded (Nakamura et al., 2012). The isomerase,
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1),
converts the pathologic cis conformer to the physiologic trans
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conformer, allowing for dephosphorylation at this site by protein
phosphatase 1 (Lu et al., 1996, 1999). It is of note, therefore, that
cis-pThr231 tau is closely associated with a number of tauopathies
including, AD, CTE and experimental CTE (Lu et al., 1996, 1999;
Liou et al., 2003; Pastorino et al., 2006; Sultana et al., 2006; Lu
and Zhou, 2007; Lim et al., 2008; Lee et al., 2011; Chen et al.,
2015; Kondo et al., 2015; Albayram et al., 2017). Given that
both cis-pThr231 tau and pThr175 tau are observed exclusively
in disease or stressed states, it is attractive to postulate that the
phosphorylation of tau protein at Thr175 increases the presence
of cis-pThr231. This may occur through either enhancing the
probability of cis phosphorylation by GSK3β or by inhibiting the
ability of PIN1 to isomerize the epitope from cis to trans. This is
the subject of current studies.
THE POTENTIAL ROLE OF COMORBID
PATHOLOGIES
The fact that other cell stressors may induce Thr175 tau protein
phosphorylation is of great significance to the mechanisms
of neurodegenerative disease. Pathologies are rarely, if ever,
observed in isolation, and it is common to identify co-
morbid pathologies in the same brain (Amador-Ortiz et al.,
2007; Josephs et al., 2014a,b; Smith, 2017). While this high
incidence of comorbidity has traditionally been attributed to
the aging process, it is increasingly evident that multiple
pathologies are present even in young cohorts of patients
afflicted with neurodegenerative disease. Therefore, there is likely
an interplay between pathological processes that drives these
co-morbid pathologies (Spires-Jones et al., 2017; Tan et al.,
2017). As such, the possibility of synergistic toxicity must be
considered when trying to understand the mechanisms that drive
neurodegenerative disease, and when attempting to treat such
diseases.
As discussed earlier, the FTLD of ALSci is classified as a
FTLD-TDP based on the prominence of pathological TDP-43
deposition. The association of TDP-43 pathology with ALS and
ALS-FTSD is well described (Arai et al., 2006; Neumann et al.,
2006). However, there is also an increasing literature describing
comorbid TDP-43 and tau pathologies, such as that observed
in AD and CTE (McKee et al., 2010; Josephs et al., 2014a,b).
The relationship between tau protein and TDP-43 pathology is
strengthened in the observation that the effective elimination of
aberrantly phosphorylated tau protein in a rodent model of CTE
can also lead to the prevention of TDP-43 pathology (Albayram
et al., 2017). It is possible that one pathological process primes
the other. In this case, the toxicity of pseudophosphorylated
Thr175Asp tau protein expression may be enhanced by the co-
expression of TDP-43, serving as a second hit to the CNS. The
potential of this synergistic toxicity is the focus of ongoing studies
in our lab.
SUMMARY
The presence of pathological tau processing is clearly evident
across a broad range of ALS patients—including those found
within the hyperendemic foci such as that seen in the western
Pacific, a smattering of case reports, and ALSci as well as FTD-
MND. This suggests that this is not a simple matter of incidental
co-occurrence. Moreover, there is solid evidence to support the
pathogenic role of pThr175 in the induction of a tauopathy, both
in vitro and in vivo, and the pathological cascade induced by
pThr175 which culminates in the generation of oligomeric tau
has been observed in a broad range of tauopathies. The issue is
therefore not whether a tauopathy exists in ALS-FTSD, but rather
the extent to which it is the driving pathology—either alone, or
in combination with the hallmark pathology of TDP-43—of the
clinical and neuropathological phenotype.
Such a proposal however leaves many unanswered questions,
including: the mechanism by which the Thr175 residue is initially
phosphorylated; how pThr175 tau leads to the activation of
GSK3β; whether pThr231 tau is necessary and sufficient to
induce neuronal dysfunction and death, or whether additional
tau protein pathological phosphorylation is needed; and what (if
any) role for the co-existent TDP-43 pathology of ALS-FTSD is
also necessary to drive the phenomenological aspects of pThr175
tau-mediated tauopathy.
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